Clinical investigation of the interface pressure in the trans-tibial socket with Dermo and Seal-In

合集下载

地塞米松玻璃体内植入剂联合抗VEGF药物治疗糖尿病性黄斑水肿的疗效研究

地塞米松玻璃体内植入剂联合抗VEGF药物治疗糖尿病性黄斑水肿的疗效研究

·37JOURNAL OF RARE AND UNCOMMON DISEASES, NOV. 2023,Vol.30, No.11, Total No.172【第一作者】昝晓宁,女,住院医师,研究方向:眼科。

E-mail:157****************【通讯作者】昝晓宁·论著·地塞米松玻璃体内植入剂联合抗VEGF药物治疗糖尿病性黄斑水肿的疗效研究*昝晓宁* 尚利晓 谢琦莲河南科技大学第一附属医院眼科 (河南 洛阳 471000)【摘要】目的 探讨地塞米松玻璃体内植入剂联合抗VEGF药物治疗糖尿病性黄斑水肿的疗效。

方法 选取2021年8月至2022年9月在本院就诊的糖尿病性黄斑水肿患者76例,随机分组,即对照组、观察组,均38例。

对照组抗VEGF药物治疗,观察组地塞米松玻璃体内植入剂联合抗VEGF药物治疗。

统计两组临床疗效、BCVA、CMT及不良反应情况。

结果 观察组临床总有效率97.37%高于对照组,P <0.05,观察组治疗后BCVA、CMT均低于对照组,P <0.05,随访至6个月后,观察组10例出现高眼压,对照组2例出现高眼压。

两组不良反应情况比较,P <0.05。

结论 地塞米松玻璃体内植入剂联合抗VEGF药物治疗糖尿病性黄斑水肿,可有效改善视力,且在改善黄斑水肿方面具有较好疗效。

【关键词】糖尿病性黄斑水肿;地塞米松玻璃体内植入剂;康柏西普;视力【中图分类号】 R587.1;R774【文献标识码】A【基金项目】河南省医学科技攻关计划项目(LHGJ20210016) DOI:10.3969/j.issn.1009-3257.2023.11.016Efficacy of Dexamethasone Intravitreal Implants Combined with Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema*ZAn Xiao-ning *, SHAng Li-xiao, XiE Qi-lian.The First Affiliated Hospital of Henan university of Science and Technology Ophthalmology, Luoyang 471000, Henan Province, ChinaAbstract: Objective To investigate the efficacy of dexamethasone intravitreal implants combined with anti-VEgF drugs in the treatment of diabetic macularedema. Methods A total of 76 patients with diabetic macular edema who were admitted to our hospital from August 2021 to September 2022 were randomly divided into control group and observation group (38 cases). The control group was treated with anti-VEgF drugs, and the observation group was treated with dexamethasone intravitreal implant combined with anti-VEgF drugs. The clinical efficacy, BCVA, CMT and adverse reactions of the two groups were analyzed. Results The total clinical effective rate of the observation group was 97.37% higher than that of the control group, P <0.05; after treatment, BCVA and CMT of the observation group were lower than that of the control group, P <0.05; after 6 months of follow-up, 10 cases in the observation group and 2 cases in the control group showed iOP . The adverse reactions of the two groups were compared, P <0.05. Conclusion edema can effectively improve visual acuity, and has a good effect on improving macular edema.Keywords: Diabetic Macular Edema; Dexamethasone Vitreous Implant; Conbercept; Visual Acuity 黄斑是位于视网膜中央的一个区域,负责视网膜中央的视觉功能。

the journal of clinical investigation投稿经历

the journal of clinical investigation投稿经历

the journal of clinical investigation投稿经历作为一位医学学者,投稿到国际知名杂志是我们追求的目标之一。

而"The Journal of Clinical Investigation"是医学领域内享有盛誉的顶级期刊之一。

在我投稿该杂志期间,经历了一些挑战和收获,下面将从几个步骤来详细阐述。

第一步:选题和撰写论文首先,我们需要选取合适的研究课题,并且展开深入的研究。

研究完成之后,我们需要开始撰写论文。

在杂志投稿之前,一定要尽可能地完善文章,并且寻求同行的意见和建议。

论文的质量和深度是审稿人和编委会决定是否发表的重要因素之一。

第二步:审稿和修改投稿到"The Journal of Clinical Investigation"后,首先会经过杂志严格的审稿过程,包括专家审查和双盲审查。

通常情况下,审稿人会提出一定的修改意见。

这时,我们需要认真阅读审稿人的意见,结合自己对论文的理解和分析,进行修改和完善。

在修改之后,需要重新投稿,并附上修改说明。

第三步:等待审稿结果一般情况下,杂志会在提交后几个月内给予审稿结果。

审稿结果可能是接受发表、拒绝发表或者要求修改再审。

如果是前两种结果,我们需要认真阅读审稿意见,并结合自己的研究成果进行反思和总结。

如果是要求修改再审,则需要根据审稿人的建议和要求进行修改,并再次投稿和说明。

第四步:发表文章如果经过多次修改后,该论文最终被"The Journal of Clinical Investigation"接受发表,恭喜您!这是对研究工作的有效认可。

但在发表文章之前,需要认真审核、修改、校对文章中的每个字和句子,以确保文章质量和流畅度。

发布之后,及时地推广和分享自己的研究成果,从而促进自己和团队研究工作的广泛传播。

在"The Journal of Clinical Investigation"投稿的经历中,不仅可以得到专家的权威意见,同时自己的思路、写作能力和科学方法也将得到提升。

张振宇主任医师辨治咳嗽晕厥综合征经验

张振宇主任医师辨治咳嗽晕厥综合征经验

Clinical Journal of Chinese Medicine 2020 V ol.(12) No.19-86-张振宇主任医师辨治咳嗽晕厥综合征经验Experience of Chief Physician Zhang Zhenyu in treating cough syncope syndrome by differention黄丽娟1 张振宇2* 李琼华2 李 璐2 张稳平2(1.昆明市官渡区关上街道社区卫生服务中心,云南 昆明,650200; 2.昆明市官渡区金马街道社区卫生服务中心,云南 昆明,650216)中图分类号:R441.5 文献标识码:A 文章编号:1674-7860(2020)19-0086- 证型:IAD 【摘 要】咳嗽晕厥综合征(Cough Syncope Syndrome , CSS )是指剧烈咳嗽情况下所导致的一过性意识丧失,短时间内能自行恢复的临床综合征,但易因摔倒而受伤。

张振宇主任医师认为本病属中医“咳嗽”“厥证”范畴,邪实正虚、痰瘀互结、阴阳之气不相顺接,发而为厥是咳嗽晕厥综合征的基本病机。

临证治疗以清肺益气,豁痰化瘀取得满意效果。

现文中选取案例一则,显示有较好的疗效。

【关键词】咳嗽晕厥综合征;张振宇;中医经验【Abstract 】Cough syncope syndrome is a clinical syndrome that can recover spontaneously in a short time due to transient loss of consciousness caused by severe cough , and is easily injured by falling. Chief physician Zhang Zhenyu believed that the disease belonged to the category of cough and syncope in TCM. The basic pathogenesis of cough syncope syndrome were Xieshi Zhengxu (邪实正虚), Tanyu Hujie (痰瘀互结) and inconsistency of Yinyang Zhi Qi (阴阳之气). The clinical treatment therapy of Qingfei Yiqi (清肺益气) and Huotan Huayu (豁痰化瘀) has achieved satisfactory results. Now, a case was reported , with good efficacy.【Keywords 】Cough syncope syndrome; Zhang Zhenyu; TCM experience doi:10.3969/j.issn.1674-7860.2020.19.029张振宇主任医师是全国名老中医学术经验继承人,师从赵淳教授,系云南省基层名中医,云南中医药大学硕士研究生指导老师,昆明市有突出贡献优秀专业技术人员,昆明市名中医专家传承工作室建设项目专家。

2016年04月急性冠脉综合征治疗新药临床研究指导原则.(英文版)

2016年04月急性冠脉综合征治疗新药临床研究指导原则.(英文版)

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom1 April 2016 1 EMA/CHMP/207892/20152 Committee for medicinal products for human use (CHMP)3 Guideline on clinical investigation of new medicinal 4products for the treatment of acute coronary syndrome 5(CPMP/EWP/570/98) 6Draft7 Draft agreed by Cardiovascular Working PartyFebruary 2016 Adopted by CHMP for release for consultation1 April 2016 Start of public consultation 27 April 2016 End of consultation (deadline for comments)31 October 2016 8 This guideline replaces 'Points to consider on the clinical investigation of new medicinal products for the 9 treatment of acute coronary syndrome (ACS) without persistent ST segment elevation' 10 (CPMP/EWP/570/98). 1112 Comments should be provided using this template . The completed comments form should be sent to CVSWPSecretariat@ema.europa.eu .13Keywords Acute coronary syndrome, STE-ACS, NSTE-ACS, guideline, CHMP1415Table of contents16Executive summary (4)171. Introduction (background) (4)182. Scope (5)193. Legal basis and relevant guidelines (5)204. Choice of efficacy criteria (endpoints) (6)214.1. All-cause mortality and CV mortality (6)224.2. New myocardial infarction (6)234.3. Revascularisation (6)244.4. Unstable angina pectoris necessitating hospitalisation (6)254.5. Stent thrombosis (6)264.6. Stroke (7)274.7. Left ventricular function and heart failure (7)284.8. Composite endpoints (7)294.9. Endpoints in fibrinolysis studies (7)305. Methods to assess efficacy (how to measure the endpoints) (8)315.1. Mortality (8)325.2. New myocardial infarction (8)335.3. Revascularisation (8)345.4. Unstable angina pectoris necessitating hospitalisation (8)355.5. Stent thrombosis (8)365.6. Ventricular function and heart failure (9)375.7. Angiographic endpoints (9)386. Selection of patients (9)396.1. Study population (9)406.1.1. STE-ACS (ST elevation acute coronary syndrome) (9)416.1.2. NSTE-ACS (Non-ST elevation acute coronary syndrome) (9)426.1.3. Unstable angina (9)436.2. Inclusion criteria for the therapeutic studies (10)446.3. Exclusion criteria for the therapeutic studies (10)456.4. Risk Stratification (10)466.5. Special populations (11)476.5.1. Older patients (11)487. Strategy and design of clinical trials (11)497.1. Clinical pharmacology (11)507.2. Therapeutic exploratory studies (12)517.2.1. Objectives (12)527.2.2. Design (12)537.3. Confirmatory Therapeutic Studies (12)547.3.1. Objectives (12)557.3.2. Background therapy (12)567.3.3. Choice of comparator (13)577.3.4. Duration of clinical studies (13)587.3.5. Analyses and subgroup analysis (13)598. Safety aspects (14)608.1. Bleedings (14)618.2. All-cause mortality (15)628.3. Thrombocytopenia (15)638.4. Rebound effect (15)648.5. Effects on laboratory variables (15)658.6. Effects on concomitant diseases (15)66References (16)6768Executive summary6970Two CHMP Guidelines have been previously developed to address clinical investigations of new71medicinal products for the treatment of acute coronary syndrome (ACS): (I) the CHMP points toconsider (PtC) on the clinical investigation of new medicinal products for the treatment of acute7273coronary syndrome without persistent ST-segment elevation (CPMP/EWP/570/98), published in 2000 74[1], and (II) the CHMP PtC on the clinical development of fibrinolytic products in the treatment of75patients with ST segment elevation myocardial infarction (CPMP/EWP/967/01), published in 2003 [2].76Since their finalisation, major developments have taken place in the definitions, diagnosis,77interventions and management of ACS, as reflected in the relevant European Society of Cardiology78(ESC) clinical practice guidelines (3, 4). Currently, an update of the above mentioned CHMP Guidelines 79is considered necessary to take these new developments into consideration based on literature review 80and experience gained with medicinal products intended for treatment during the acute phase and81beyond. The present update includes the following changes: 1) guidance addressing both ST-segment 82elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction83(NSTEMI), as well as unstable angina (UA), 2) update in their definitions, 3) risk stratification using84different scoring systems, 4) investigated endpoints, and 5) clinical developments of new medicinal85products beyond the acute stage, including agents other than antiplatelets and anticoagulants.1. Introduction (background)8687Cardiovascular diseases are currently the leading cause of death in industrialized countries and also 88expected to become so in emerging countries by 2020 [3, 4]. Among these, coronary artery disease 89(CAD) is the most prevalent manifestation and is associated with high mortality and morbidity. ACS 90has evolved as a useful operational term to refer to any constellation of clinical symptoms that are91compatible with acute myocardial ischemia. It encompasses (STEMI), NSTEMI, and UA.92ACS represents a life-threatening manifestation of atherosclerosis. It is usually precipitated by acute 93thrombosis induced by a ruptured or eroded atherosclerotic coronary plaque, with or without94concomitant vasoconstriction, causing a sudden and critical reduction in blood flow. In the complex95process of plaque disruption, inflammation was revealed as a key pathophysiological element. Non-96atherosclerotic aetiologies are rare e.g. such as arteritis and dissection.97The leading symptom of ACS is typically chest pain. Patients with acute chest pain and persistent (>20 min) ST-segment elevation have ST-elevation ACS (STE-ACS) that generally reflect an acute total9899coronary occlusion. Patients with acute chest pain but without persistent ST-segment elevation have 100rather persistent or transient ST-segment depression or T-wave inversion, flat T waves, pseudo-101normalization of T waves, or no ECG changes. At presentation, based on the measurement of102troponins, it is possible to further discriminate between the working diagnosis of non-ST-elevation ACS 103(NSTE-ACS) and unstable angina.104NSTE-ACS is more frequent than STE-ACS [5] with an annual incidence around 3 per 1000 inhabitants, 105but varying between countries [6]. Hospital mortality is higher in patients with STEMI than among 106those with NSTEMI (7% vs. 3–5%, respectively), but at 6 months the mortality rates are very similar 107in both conditions (12% and 13%, respectively) [5,7,8]. Long term follow-up shows that death rates 108were higher among patients with NSTE-ACS than with STE-ACS, with a two-fold difference at 4 years[8]. This difference in mid- and long-term evolution may be due to different patient profiles, since 109110NSTE-ACS patients tend to be older with more co-morbidities, especially diabetes and renal failure.2. Scope111112The aim of this guideline is to provide guidance when performing trials to develop medicinal products 113in the management of ACS. The primary goals of therapy for patients with ACS are to:1. Treat acute, life-threatening complications of ACS, such as serious arrhythmias, pulmonary 114115oedema, cardiogenic shock and mechanical complications of acute myocardial infarction (AMI). [9] 1162. Reduce the amount of myocardial necrosis that occurs in patients with AMI, thus preserving 117left ventricular (LV) function, preventing heart failure (HF), and limiting other cardiovascular118complications.1193. Prevent major adverse cardiac events like death, non-fatal myocardial infarction (MI), andneed for urgent revascularization.120121The focus in this Guideline concerns mainly the medical treatment of ACS (treatment goals 2 and 3). 122The choice of interventional procedures [percutaneous coronary intervention (PCI) or coronary artery 123bypass graft CABG)] falls outside the scope of this guideline.3. Legal basis and relevant guidelines124125This guideline has to be read in conjunction with the introduction and general principles and parts I 126and II of the Annex I to Directive 2001/83 as amended.127Pertinent elements outlined in current and future EU and ICH guidelines, should also be taken into 128account, especially those listed below:129•Dose-Response Information to Support Drug Registration (ICH E4; CPMP/ICH/378/95).130•Statistical Principles for Clinical Trials (ICH E9; CPMP/ICH/363/96).131•Choice of Control Group and Related Issues in Clinical Trials (ICH E10; CPMP/ICH/364/96).132•Points to consider on an Application with 1) Meta-analyses 2) One pivotal study133(CPMP/EWP/2330/99).134•Points to consider on multiplicity issues in clinical trials (CPMP/EWP/908/99).135•Investigation of subgroups in confirmatory clinical trials (EMA/CHMP/539146/2013).136•The Extent of Population Exposure to Assess Clinical Safety for Drugs (ICH E1A;137CPMP/ICH/375/95).138•Pharmacokinetic Studies in Man (3CC3A).139•Studies in Support of Special Populations: Geriatrics (ICH E7 CHMP/ICH/379/95) and related Q&A 140document (EMA/CHMP/ICH/604661/2009).141•Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95).142•Reporting the Results of Population Pharmacokinetic Analyses (CHMP/EWP/185990/06).143•Reflection paper on the extrapolation of results from clinical studies conducted outside the EU to 144the EU-population (EMEA/CHMP/EWP/692702/2008).145•Draft Guideline on clinical investigation of medicinal products for the treatment of chronic heart 146failure (EMA/392958/2015 )•Guideline on clinical investigation of medicinal products for the treatment of acute heart failure147148(CPMP/EWP/2986/03 Rev. 1)4. Choice of efficacy criteria (endpoints)149150Definitions of clinical endpoints in confirmatory trials should be in line with the relevant clinical151guidelines to facilitate interpretation of the results, to allow comparisons across clinical studies and to 152extrapolate to clinical practice. Endpoints should be centrally adjudicated by a blinded committee. The 153following endpoints are relevant to the investigation of efficacy in patients with ACS.4.1. All-cause mortality and CV mortality154155As one of the goals of treatment of ACS is reduction of mortality, this is an important endpoint to156measure. There is an ongoing debate around the use of all-cause versus cardiovascular mortality in 157cardiovascular (CV) trials. All cause mortality is the most important endpoint in clinical trials for the 158estimation of the benefit-risk balance of a drug, in particular when investigating newer medicinal159products with possible safety issues. On the other hand, CV mortality is more specifically linked to the 160mode of action of CV medicinal products/intervention and is especially relevant when the earliest part 161of the follow up is assessed. The choice is also dependent on the objective of the study i.e. in non-162inferiority trials, CVmortality may be preferred while in superiority trials all cause mortality is usually 163used. In fibrinolysis studies, all cause mortality is preferred (see section 4.9).164As such, one of the two mortality endpoints should be included as a component of the primary165endpoint, with the other investigated as a key secondary endpoint.4.2. New myocardial infarction166167New onset MIis a relevant endpoint in studies of ACS and should always be investigated. The definition 168of MI has evolved through the years; at the time of drafting of this Guideline, the third universal169definition of MI is applicable [10]. Criteria of MI are the same as those used to define the index event 170(see below).4.3. Revascularisation171172Some clinical trials have included revascularization endpoints (PCI or CABG) as part of the primary 173composite with conflicting results [11, 12]. Such endpoints are considered more relevant tointerventional studies, and in the scope of this Guideline, their inclusion as a primary endpoint should 174175be clearly justified and their assessment pre-defined and systematically assessed.4.4. Unstable angina pectoris necessitating hospitalisation176177Unstable angina has been investigated in ACS clinical trials. Due to the varying definitions used, the 178associated subjectivity and the influence of local clinical practice, this endpoint is not encouraged to be 179included in the composite primary endpoint.4.5. Stent thrombosis180181Stent thrombosis (ST) is a rare event that can have fatal consequences. ST has been captured in some 182registration studies, but not consistently in the primary endpoint (PEP). The investigation of ST as part 183of the primary endpoint is not encouraged due to the uncertainty of the clinical relevance of all184captured events, except for the "definite" subcategory. Another category identified by the timing isintra-procedural stent thrombosis (IPST), which is a rare event indicating the development of occlusive 185186or non-occlusive new thrombus in or adjacent to a recently implanted stent before the PCI procedure is187completed. Some recent studies [13,14] show that these events may be of prognostic value. As such they should also be collected and presented as secondary endpoint but not included in the analysis of 188189ST.4.6. Stroke190191Stroke should be defined by a generally accepted definition [15]. Clinical studies in ACS have used192non-fatal stroke in the primary endpoint , including any types of strokes. However it is preferred to193include only ischemic strokes in the primary endpoint, as this is the true measure of efficacy;194haemorrhagic stroke should be included as a safety endpoint. An ischaemic stroke with haemorrhagic195conversion should be considered as “primary ischaemic”. The subgroup of “undefined strokes” should196be as small as possible in order to be able to properly assess the effect of the study treatment. In case 197all types of strokes are included in the primary endpoint, a sensitivity analysis including only ischemic198stroke should be submitted.4.7. Left ventricular function and heart failure199Some medicinal products such as modulators of reperfusion injury or inflammation, or gene/cell200201therapy are developed to improve myocardial function and reduce the occurrence of HF. In these202cases, measurement of myocardial function could be a relevant endpoint to investigate the mechanismof action. In phase III studies, these endpoints can be investigated as secondary endpoints to support 203204the clinical endpoints. Occurrence of HF should be considered as a clinical endpoint in phase III studies205aimed at showing benefit in long-term cardiovascular outcome. All-cause mortality and long term206follow-up are mandatory in studies with novel interventions.4.8. Composite endpoints207Due to the rather low incidence of cardiovascular events during the follow-up period after the acute 208209phase of the ACS, composite endpoints consisting of relevant components are acceptable, both as210primary and secondary endpoints. The composite of CV death, non-fatal MI and non-fatal stroke (Major211Adverse Cardiovascular Events, [MACE]) has commonly been used in registration studies, with non-212fatal strokes showing limited contribution to the results. As such, it is preferred to investigate the213composite of death and non-fatal MI in confirmatory studies; non-fatal ischaemic stroke could beincluded in the composite if justified. Sometimes different definitions of MACE are being used with214215novel therapies [16], that should be justified when used in place of MACE. The inclusion of less216objective and clinically derived outcomes in the same composite is generally not encouraged, as they217may either drive the efficacy or dilute the results. In case these endpoints are included they have to be218stringently defined, and adjudicated. Each component of the primary composite endpoint should be219analysed as secondary endpoint.220The net clinical benefit that includes both benefit and safety issues of the studied drug may be used as221a secondary endpoint to be evaluated if it contributes to the discussion on the benefit-risk balance of222the studied drug.4.9. Endpoints in fibrinolysis studies223224In fibrinolysis studies, angiographic studies using the TIMI (Thrombolysisi in Myocardial Infarction)perfusion grades as evaluation criteria are often used. However, complete recanalization cannot be 225226considered as a surrogate for survival when assessing fibrinolytic drugs, as some medicinal productsproviding higher complete recanalization rates than alteplase, failed to demonstrate additional survival 227228benefit. For this reason, all cause mortality is the most relevant endpoint or a combined endpoint as 229previously discussed (see 4.1). Secondary endpoints such as heart failure hospitalisations, left230ventricular function, ventricular arrhythmias, the need for rescue recanalization (emergent and/or231planned) should also be considered and justified.5. Methods to assess efficacy (how to measure the232endpoints)2335.1. Mortality234235Definition of CV death should be clearly defined, in line with acceptable standards [17]. It is mandatory 236to report and centrally adjudicate all mortality data where survival is an endpoint of the study.237Assessment of cardiovascular mortality will require censoring of other “types” of mortality, which may 238complicate its interpretation, in particular when non-CV deaths are in high proportion.5.2. New myocardial infarction239240The diagnostic of MI is based on the detection of a rise and/or fall of cardiac biomarker values241[preferably cardiac troponin (cTn)] with at least one value above the 99th percentile upper reference 242limit (URL). All MIs should be collected and also classified by their different sub types (i.e,243spontaneous, secondary to an ischemic imbalance, related to PCI, related to ST or CABG) [10]. This is 244particularly important considering the different prognostic values of each type of MI. For the same 245reason and to support the clinical relevance of post procedural MIs, these events should be presented 246with higher cut-off values (≥ 5 and ≥10x upper level of normal ULN, in case of CK-MB or ≥70x ULN of 247cTn) [18]. These higher cut-off values can also help in diagnosing MIs in the setting of elevated248baseline biomarkers, which is a problematic situation. In such cases, serial measurements of the249biomarkers are necessary, in addition to new ECG changes or signs of worsening of cardiac function, 250e.g. HFor hypotension [18].5.3. Revascularisation251252The underlying cause of revascularization should be identified: restenosis, ST or disease progression. 253In the latter case target vessel revascularization (TVR) could be included. Early target lesion eventsafter revascularization (before 30 days) are more likely to be caused by an angiographic complication 254255and should preferably be included as safety endpoint (see ST).5.4. Unstable angina pectoris necessitating hospitalisation256257When investigated, robust definitions should be employed. In order to support the seriousness of the 258event it should also be shown that it has led to a revascularisation procedure. Since a medicinalproduct that prevents death and/or new MI might result in more patients suffering from UA, the259260analysis of this endpoint should take into account censoring issues as well.5.5. Stent thrombosis261262ST should be collected and classified as definite, probable and possible in line with acceptable263definitions [19]. In addition, the timing of ST should be documented (acute, sub-acute, late and very 264late), as risk factors and clinical sequels differ with timing.5.6. Ventricular function and heart failure265266Investigation of cardiac function should follow state of the art methods. This can include among others 267measurement of ventricular function by isotopic method and/or by cardiac magnetic resonance imaging 268and/or echocardiography. Investigation of HFshould follow the relevant CHMP guidelines.5.7. Angiographic endpoints269270Angiograms should undergo central blinded reading. In principle, the rate of TIMI 3 flow (complete 271revascularization) of the infarct related artery at 90 minutes is considered the most relevant272angiographic endpoint, as it has been shown to correlate with an improved outcome in terms of273mortality and left ventricular function. An earlier evaluation of the patency pattern (i.e. 30 and 60274minutes) may provide important information on the speed of recanalization. Whatever is the time-point 275selected as primary outcome, it must be properly justified and pre-specified in the clinical trial.6. Selection of patients2766.1. Study population277The definition of the different ACS subtypes should be based on current guidelines/universal definition 278279of MI including STEMI and NSTEMI as well as UA [3, 4, 10].6.1.1. STE-ACS (ST elevation acute coronary syndrome)280281In patients with acute chest pain and persistent (>20 min) ST-segment elevation on ECG the282diagnostic of STE-ACS is made [3]. This condition generally reflects an acute total coronary occlusion.Most patients will ultimately develop an ST-elevation myocardial infarction (STEMI) with the criteria of 283284acute myocardial infarction described before [see 5.2].6.1.2. NSTE-ACS (Non-ST elevation acute coronary syndrome)285286In patients with acute chest pain but no persistent ST-segment elevation the diagnostic of NSTE-ACS is 287made [4]. ECG changes may include transient ST-segment elevation, persistent or transient ST-288segment depression, T-wave inversion, flat T waves or pseudo-normalization of T waves or the ECG 289may be normal. The clinical spectrum of non-ST-elevation ACS (NSTE-ACS) may range from patients 290free of symptoms at presentation to individuals with ongoing ischaemia, electrical or haemodynamic 291instability or cardiac arrest. The pathological correlate at the myocardial level is cardiomyocyte292necrosis (NSTEMI) or, less frequently, myocardial ischaemia without cell loss (UA). Currently, cardiac 293troponins play a central role in establishing a diagnosis and stratifying risk, and make it possible to 294distinguish between NSTEMI and UA[4].6.1.3. Unstable angina295296Unstable angina (UA) is defined as myocardial ischemia at rest or minimal exertion in the absence of 297cardiomyocytes necrosis, i.e. without troponin elevation. Among NSTE-ACS population, the higher298sensitivity of troponin has resulted in an increase in the detection of MI [4]; the diagnosis of UAis less 299frequently made.6.2. Inclusion criteria for the therapeutic studies300301Inclusion of both STEMI and NSTEMI and/or NSTE-ACS patients in the same clinical trial (or not)302should be justified based on the mechanism of action of the investigated product and the proposed 303time of intervention. If both subgroups are investigated in the same trial, both subgroups should be 304well represented. For interventions aimed at post-acute and longer term phases (secondary305prevention or plaque stabilisation) it may be justified to address both conditions in the same clinical 306trial. Time of inclusion of the patients in relation to the index event should be set and adequately307discussed a priori.308Patients with unstable angina represent a different risk category and prognosis that necessitates309different interventions than NSTEMI patients. However, during the acute presentation of NSTE-ACS it may be difficult to discriminate NSTEMI from UA so both groups have been included in some clinical 310311studies. In general, the investigation of interventions in these patients is encouraged, but preferably in 312separate clinical trials.If fibrinolysis is considered, inclusion criteria should be in line with the current treatment guidelines 313314concerning the inclusion for fibrinolysis [3].6.3. Exclusion criteria for the therapeutic studies315316If the patients do not fulfil the above criteria for ACS they should be excluded from the ACS studies. 317Other life-threatening conditions presenting with chest pain, such as dissecting aneurysm,318myopericarditis or pulmonary embolism may also result in elevated troponins and should always be 319considered as differential diagnoses [4].320If drugs interfering with the haemostatic system are tested, patients with a significant risk of bleeding 321(e.g. recent stroke, recent bleeding, major trauma or surgical intervention) and/or a propensity to 322bleed (e.g. thrombocytopenia, clotting disturbances, intracranial vascular diseases, peptic ulcers,323haemophilia) should be excluded from participation in the clinical studies.324Attention should be paid to the time elapsed between a previous application of antiplatelet or325anticoagulant acting agent beforehand and the administration of study drug (e.g. the pharmacokinetic 326[PK] and even more importantly, the pharmacodynamic [PD] half-life of these previously administered 327drugs).328For reasons of generalisability of the study results to the future target population it is strongly advised 329not to define the exclusion criteria too narrow, i.e. polymorbid patients (e.g. renal and/or hepatic330impairment, heart failure), should not automatically be excluded from the main therapeutic clinical 331trials.332When fibrinolysis is considered, exclusion criteria for fibrinolysis should be strictly respected [3].6.4. Risk Stratification333334In clinical trials, the ability of the therapy to demonstrate a treatment effect may depend on the335underlying risk and expected event rates. Enrichment strategies are sometimes used in trials to obtain 336the required number of events with a reasonable time in specific subgroups who are likely to exhibit a 337higher event rate than the overall target population and potentially larger treatment effect. In thatcase, it has to be shown that the results of this enriched study population can be extrapolated to the 338339general population.。

clinical investigation plan

clinical investigation plan

clinical investigation planClinical Investigation Plan (CIP)Introduction:The clinical investigation plan (CIP) is a crucial document that outlines the strategy and methodology for conducting clinical trials or studies. It serves as a roadmap for researchers and ensures that the investigation is conducted in an ethical, scientifically rigorous, and transparent manner. This comprehensive plan provides detailed information about the study design, subject selection, data collection, analysis, and reporting.Study Objectives:The CIP begins with a clear statement of the study objectives. These objectives should be specific, measurable, achievable, relevant, and time-bound (SMART). They should address the research question(s) or hypothesis being tested and outline the desired outcomes of the investigation.Background and Rationale:In this section of the CIP, the research context and rationale for conducting the study are provided. This includes a literature review summarizing relevant previous research, the current knowledge gap, and the potential benefits of the proposed investigation. The rationale should address the need for the study and highlight its potential contribution to scientific knowledge or clinical practice. Study Design:The CIP details the study design, which may be observational (e.g., cohort, case-control) or experimental (e.g., randomized controlledtrial). The rationale for choosing a particular design is explained, along with any potential limitations associated with the design choice. The study design section should also include information about the study duration, endpoints, and sample size estimation. Subject Selection:The CIP outlines the criteria for subject selection, ensuring that participants meet specific eligibility criteria. It describes the method of subject recruitment and provides details about the informed consent process, ensuring that participants understand the study purpose, procedures, and potential risks. The plan should include a description of any inclusion or exclusion criteria, as well as the process for randomization (if applicable) and blinding. Data Collection:This section of the CIP describes the data collection procedures, including the tools, instruments, or measurements to be used. It outlines the frequency and duration of assessments and clarifies who will collect the data and how it will be managed, stored, and protected to ensure patient confidentiality.Statistical Analysis:The CIP delineates the statistical methods that will be used to analyze the data. It includes a detailed description of the primary and secondary endpoints, as well as any planned subgroup analyses or exploratory endpoints. The plan should also address how missing data, outliers, or confounding factors will be handled. Safety and Ethical Considerations:The CIP emphasizes the safety of participants and outlines thesteps taken to monitor and manage adverse events. It includes details about the ethical principles, such as informed consent, privacy protection, and data confidentiality. The plan should also specify whether an independent data monitoring committee will be involved and describe its responsibilities.Timeline and Budget:The CIP provides a timeline for the entire investigation, including subject recruitment, data collection, analysis, and reporting. It also includes a budget estimate, covering both direct costs (e.g., personnel, supplies, equipment) and indirect costs (e.g., overhead, administrative fees).Conclusion:A well-written CIP is essential for ensuring that a clinical investigation is conducted efficiently, ethically, and with scientific rigor. It provides a detailed roadmap for researchers and serves as a reference document throughout the study. By addressing study objectives, design, subject selection, data collection, analysis, and ethical considerations, the CIP helps to ensure high-quality research and accurate reporting of study outcomes.。

CLINICAL INVESTIGATIONS

CLINICAL INVESTIGATIONS

EUROPEAN COMMISSIONDIRECTORATE GENERAL for HEALTH and CONSUMERSConsumer AffairsCosmetics and Medical DevicesMEDDEV 2.7/3December 2010GUIDELINES ON MEDICAL DEVICESCLINICAL INVESTIGATIONS:SERIOUS ADVERSE EVENT REPORTINGUNDER D IRECTIVES 90/385/EEC AND 93/42/EEC.The present guidelines are part of a set of guidelines relating to questions of application of EU-Directives on MEDICAL DEVICEs. They are legally not binding. The guidelines have been carefully drafted through a process of intensive consultation of the various interested parties (competent authorities, Commission services, industries, other interested parties) during which intermediate drafts were circulated and comments were taken up in the document. Therefore, this document reflects positions taken by representatives of interested parties in the medical devices sector.These guidelines incorporate changes introduced by Directive 2007/47/EC amending Council Directive 90/385/EEC and Council Directive 93/42/EEC.1. OBJECTIVEThis guidance defines Serious Adverse Event (SAE) reporting modalities and includes a summary tabulation reporting format1. Its objective is to contribute to the notification of SAEs to allconcerned National Competent Authorities (NCAs2) in the context of clinical investigations inline with the requirements of Annex 7 of Directive 90/385/EEC and Annex X of Directive93/42/EEC, as amended by Directive 2007/47/EC.According to annex 7 of Directive 90/385/EEC and to annex X of Directive 93/42/EEC: “Allserious adverse events must be fully recorded and immediately notified to all competentauthorities of the Member States in which the clinical investigation is being performed."2. SCOPEThe reporting modalities and format set out in this guidance apply to pre-market3 clinicalinvestigations4-5 conducted with:a.Non-CE marked devices,a.b.C E marked devices used outside the intended use(s) covered by the CE marking.The tabular format featured in the Appendix needs to be updated for each reportable event or for new findings/updates to already reported events. It shall be transmitted to all NCAs where theclinical investigation is being performed.3. DEFINITIONS (from ISO/FDIS 14155)Adverse Device Effect (ADE)Adverse event related to the use of an investigational medical device.NOTE 1- This includes any adverse event resulting from insufficiencies or inadequacies in theinstructions for use, the deployment, the implantation, the installation, the operation, or anymalfunction of the investigational medical device.NOTE 2- This includes any event that is a result of a use error or intentional misuse.Adverse Event (AE)Any untoward medical occurrence, unintended disease or injury or any untoward clinical signs(including an abnormal laboratory finding) in subjects, users or other persons whether or notrelated to the investigational medical device.1 A template for individual reporting of SAEs is under preparation to harmonize individual SAE forms in case NCAs require individual reporting for the SAEs occurring within their jurisdictions. Further revisions of these template documents may become necessary in line with the forthcoming corresponding GHTF-Guidance.2 For the purpose of this guidance," NCAs" encompass the National Competent Authorities of the EU, the EEA and of Switzerland and Turkey.3 A specific guidance on Post Market Clinical Follow-Up Studies is in preparation.4 - This includes pre-market clinical investigations:which started prior to 21 March 2010 and are continued after that date. [Note: reporting of SAE as covered in this guidance only started on 21 March 2010 with the implementation of Directive 2007/47/EC and is not retrospective.to SAEs that occurred prior to 21 March 2010].- For pre-market clinical investigations involving CE marked comparator devices, SAEs occurring in or to subjects that are in the comparator arm of an investigation shall also be reported in accordance with these guidelines.5 Where the right to bear the CE marking has been obtained before the end of the clinical investigation, the SAE reporting continues until completion of the investigation, according to the clinical investigation plan.NOTE 1: This includes events related to the investigational device or the comparator.NOTE 2: This includes events related to the procedures involved (any procedure in the clinicalinvestigation plan).NOTE 3: For users or other persons this is restricted to events related to the investigationalmedical device.Device deficiencyInadequacy of a medical device related to its identity, quality, durability, reliability, safety orperformance, such as malfunction, misuse or use error and inadequate labeling.Investigational medical deviceMedical device being assessed for safety or performance in a clinical investigation NOTE: This includes medical devices already on the market that are being evaluated for new intended uses, new populations, new materials or design changes.Serious Adverse Device Effect (SADE)Adverse device effect that has resulted in any of the consequences characteristic of a seriousadverse event.Serious Adverse Event (SAE)Adverse event that:a) led to a death,b) led to a serious deterioration in health that either:1) resulted in a life-threatening illness or injury, or2) resulted in a permanent impairment of a body structure or a body function, or3) required in-patient hospitalization or prolongation of existing hospitalization, or4) resulted in medical or surgical intervention to prevent life threatening illness or injuryor permanent impairment to a body structure or a body function.c) led to fetal distress, fetal death or a congenital abnormality or birth defect.NOTE 1: This includes device deficiencies that might have led to a serious adverse event if a)suitable action had not been taken or b) intervention had not been made or c) if circumstances had been less fortunate. These are handled under the SAE reporting system.NOTE 2: A planned hospitalization for pre-existing condition, or a procedure required by theClinical Investigation Plan, without a serious deterioration in health, is not considered to be aserious adverse event.Unanticipated Serious Adverse Device Effect (USADE)Serious adverse device effect which by its nature, incidence, severity or outcome has not beenidentified in the current version of the risk analysis report.NOTE: Anticipated: an effect which by its nature, incidence, severity or outcome has beenpreviously identified in the risk analysis report4. REPORTABLE EVENTS UNDER ANNEX 7 AND ANNEX X OF DIRECTIVES 90/385/EEC AND 93/42/EEC RESPECTIVELY.For the purpose of this guidance and based on the definitions above, the following events areconsidered reportable events in accordance with Annex 7, section 2.3.5 and Annex X, section 2.3.5 of the above mentioned Directives:-any SAE,-any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not been taken or b) intervention had not been made or c) if circumstances hadbeen less fortunate-new findings/updates in relation to already reported events.Reportable events occurring in Third Countries6 in which a clinical investigation is performed under the same clinical investigation plan, have to be reported in accordance with this guidance.5. REPORT BY WHOM.Reportable events have to be reported by the sponsor of the clinical investigation, which could be the manufacturer (MFR), the authorized representative (AR) or another person or entity7-8.6. REPORT TO WHOM.Reportable events must be reported at the same time to all NCAs where the clinical investigation has commenced9-10 using the summary tabulation featured in the Appendix.A list of clinical investigation contact points within the NCAs is published at the Commission'shomepage.7. REPORTING TIMELINES7.1 Report by sponsor to NCAs.The sponsor must report to the NCAs where the clinical investigation has commenced: • a SAE which indicates an imminent risk of death, serious injury, or serious illness and that requires prompt remedial action for other patients/subjects, users or other persons11 or a newfinding to it: immediately, but not later than 2 calendar days after awareness by sponsor of anew reportable event or of new information in relation with an already reported event.•any other reportable events as described in section 4 or a new finding/update to it: immediately, but not later than 7 calendar days following the date of awareness by the sponsorof the new reportable event or of new information in relation with an already reported event.6 Countries other than Switzerland, Turkey and those belonging to the EU and the EEA.7 Note: Member States may also require separate reporting by clinical investigators/medical professionals.8 Note: SAEs concerning CE marked devices (e.g. comparators) which meet the vigilance reporting criteria may also need to be handled under the post-market surveillance/vigilance system.9 For the purpose of this guidance, an investigation is considered to have commenced in an individual Member State when the sponsor is authorised to start the investigation in accordance with the notification procedures in that Member State.10 Note: Member States may also require separate reporting to the Ethics Committee(s) and/or separate reporting to the other clinical investigators/study centers involved in the clinical investigation.11This includes:•events that are of significant and unexpected nature such that they become alarming as a potential public health hazard, e.g. human immunodeficiency virus (HIV) or Creutzfeldt-Jacob Disease (CJD). These concerns may beidentified by either the NCA or the MFR.•the possibility of multiple deaths occurring at short intervals.7.2 Report by the investigator to the sponsorThe sponsor shall implement and maintain a system to ensure that the reporting of the reportable events will be provided by the investigator to the sponsor in acceptable timely conditions, but not later than within 3 calendar days after the occurrence of the event.In some cases, a different periodicity or different modalities12 may be agreed by the participatingNCAs according to the investigational design and to the pathology under clinical investigation. This would allow adequate provision for clinical investigations (e.g. palliative oncology…) in which SAE frequency is expected to be high due to progression of the disease. This needs to be agreed between the sponsor and relevant NCAs.8. REPORTING FORMThe reporting form template for the summary SAE tabulation is given in the Appendix of thisdocument.The table gives a cumulative overview of the reportable events per clinical investigation and will be updated and transmitted to participating NCAs each time a new reportable event or a newfinding to an already reported event is to be reported. More detailed information has to beprovided on request of an NCA.The sponsor shall identify the new/updated information in the status column of the tabular form featured in the Appendix as:a = added = new reportable event;m = modified = new finding/update to an already reported event;u = unchanged.Changes in a line should be highlighted in bold and/or color in the respective column.The reporting form is study specific and covers only a given clinical investigation, defined by a distinct clinical investigation plan. English is the recommended language for the reporting form.The report should be sent by email preferably in Excel or equivalent format to the participatingNCAs.R EFERENCES:1.Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relatingto active implantable medical devices, last amended by Directive 2007/47/EC.2.Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, last amended by Directive2007/47/EC.3.ISO/FDIS 14155:2010 Clinical investigation of medical devices for human subjects – Good clinical practice 12 in line with Annex 7.2.3.5 of Directive 90/385/EEC and Annex X.2.3.5 of Directive 93/42/EECA PPENDIX –R EPORTING FORMMEDDEV 2.7/3 SAE Report Table- V1 EUDAMED - ID:Title of ClinicalInvestigation:CIP Number:Contact person(Name, Address,E-Mail, TelephoneNumber)Device type:MS+NCA Reference Numbersfor all participating Countries:Reference Member State:No. of Patients enrolled to date (date of report):No. of Invest. Devices used to dateDate of Report:Status: a, m, uDateSponsorreceivedReport ofSAECountryStudyCenterPatient IDCodeDate ofProcedure/First UseDate ofEventOnsetEvent:OrganSystemDescriptionof eventaction/treatment/patientoutcomeAssessment ofRelationshipto Procedure:YesNoPossiblyAssessmentofRelationshiptoInvestigationalDevice:YesNoPossiblyUnanticipatedSADE yes/NoTreatmentArm:InvestigationalDevice/ControlGroup/blinded/n.a.Event Status:Resolved/Resolved withSequelae/Ongoing/DeathDate ofEventResolutionNote: Submission of this report does not, in itself, represent a conclusion by the sponsor or the competent authority that the content of this report is complete or that the device(s) listed failed in any manner and/or that the device(s) caused or contributed to the alleged death or deterioration in the state of the health of any person.Page 6。

人工智能医疗器械注册审查指导原则 英文

人工智能医疗器械注册审查指导原则 英文

人工智能医疗器械注册审查指导原则英文Principles for the Review of Registration of Artificial Intelligence Medical Devices1. Purpose of the GuidelinesThese guidelines are intended to provide a framework for the review of registration of artificial intelligence medical devices by regulatory agencies. They aim to ensure the safety, efficacy, and quality of such devices, as well as promote innovation and facilitate market access.2. Definition of Artificial Intelligence Medical DeviceAn artificial intelligence medical device is a software or hardware system that uses artificial intelligence techniques to assist in the diagnosis, treatment, or prevention of diseases or medical conditions.3. Risk ClassificationArtificial intelligence medical devices should be classified according to their risk levels, taking into consideration the intended use, the complexity of the algorithm, and the potential impact on patient safety. This classification will determine the appropriate regulatory requirements and level of scrutiny.4. Data RequirementsThe review of artificial intelligence medical devices should evaluate the quality and reliability of the data used to train and validate the algorithm. This includes the source of the data, its representativeness, accuracy, completeness, and relevance to the intended use of the device.5. Algorithm ValidationThe algorithm used in the artificial intelligence medical device should be validated to ensure its accuracy, reliability, and generalizability. This may involve testing the algorithm on different datasets, evaluating its performance against established standards, and conducting clinical trials or real-world studies.6. Transparency and InterpretabilityThe review should assess the transparency and interpretability of the artificial intelligence medical device. The device should provide clear and understandable explanations of its decisions or recommendations, and allow healthcare professionals to verify and validate its outputs.7. Safety and EfficacyThe review should evaluate the safety and efficacy of the artificial intelligence medical device. This includes assessing its ability to detect, diagnose, or predict medical conditions accurately, its potential risks or adverse effects, and its clinical benefits compared to existing methods or devices.8. Post-Market SurveillanceRegulatory agencies should establish post-market surveillance systems to monitor the safety and performance of artificial intelligence medical devices after they are placed on the market. This includes the collection of real-world data, reporting of adverse events, and ongoing evaluation of the device’s performance and effectiveness.9. Regulatory HarmonizationRegulatory agencies should collaborate and harmonize their review processes and requirements for artificial intelligence medical devices to facilitate global market access and ensure consistent evaluation of safety and efficacy.10. Ethical ConsiderationsThe review should take into account ethical considerations, such as privacy, data protection, and fairness. Artificial intelligence medical devices should comply with relevant ethical standards and regulations, and respect patient autonomy and confidentiality. Note: These guidelines are intended as general principles and may need to be adapted or supplemented based on the specific regulatory context and requirements of each jurisdiction.。

journal of clinical investigation 格式 -回复

journal of clinical investigation 格式 -回复

journal of clinical investigation格式 -回复1. 什么是《Journal of Clinical Investigation》?《Journal of Clinical Investigation》是一本医学期刊,以临床医疗和转化医学研究为主要内容。

它旨在发表原创研究文章、评论、综述和专题研究等,以推动医学科学的发展和逐步实施临床应用。

2. 为何选择《Journal of Clinical Investigation》?选择《Journal of Clinical Investigation》的原因是因为它是一本具有较高影响因子和声誉的期刊,它的文章都经过严格的同行评审和质量控制,可以保证发表的文章具有较高的科学价值和可信度。

3. 文章选题和目的:本文选择的主题是“遗传因素在癌症发生中的作用”。

目的是通过全面分析最新的研究成果,探讨遗传因素对癌症发生的影响,并提供新的思路和方向,以改善癌症的预防和治疗策略。

4. 文章结构:本文将按照以下结构展开:引言、遗传因素与癌症的关联、常见癌症类型及其遗传基础、遗传因素对癌症预后的影响、遗传因素在抗癌药物疗效中的作用、遗传因素与个体化医疗、总结与展望。

5. 引言:引言部分将介绍癌症作为一种复杂的疾病,其发生和发展不仅受环境因素影响,遗传因素也具有重要作用。

文献调查将回顾已有的研究结果,概述遗传因素与癌症发生之间的关联,并指出本文研究的目的和意义。

6. 遗传因素与癌症的关联:通过综述最近的研究成果,将详细阐述遗传因素在癌症发生中的重要性。

涉及到的内容包括突变的遗传模式、癌症家族性疾病的研究、肿瘤易感基因的鉴定等。

7. 常见癌症类型及其遗传基础:这一部分将重点介绍常见癌症类型的遗传基础。

例如,乳腺癌、结直肠癌和肺癌等癌症的遗传因素和基因突变。

还将涉及到遗传性癌症综合征的研究,如布什蒂-雷布林综合征。

8. 遗传因素对癌症预后的影响:这一部分将探讨遗传因素对癌症预后的影响。

双语病例——神经结节病

双语病例——神经结节病

双语病例——神经结节病朗读老师:Jane 天津某医院翻译老师:张翠浙江省立同德医院审校老师:姜春雷青岛市第九人民医院57-year-old woman with fatigue, weakness, headaches57 岁女性,疲劳、乏力、头痛History and MR images病史和磁共振图像History: A 57-year-old woman presents with progressive fatigue, weakness, and headaches.病史:一名 57 岁女性表现为进行性疲劳、乏力和头痛。

Axial T2-weighted, fluid-attenuated inversion-recovery (FLAIR), and precontrast T1-weighted MR images, as well as axial and coronal postcontrast T1-weighted images, are shown below. Click to enlarge.横断位 T2 加权、液体衰减反转恢复 (FLAIR) 和 T1 加权 MR 图像,以及横断位和冠状位增强 T1 加权图像如下所示。

点击放大。

Findings 结果MRI demonstrates innumerable punctate T2/FLAIR hyperintense, enhancing nodules in the centrum semiovale, corona radiata, basal ganglia, brainstem, and visualized upper cervical spine bilaterally. Many of these nodules appear near the deep penetrating vessels along the perivascular spaces.MRI 显示无数点状T2/FLAIR 高信号,双侧半卵圆中心、放射冠、基底神经节、脑干和上颈髓中强化的结节。

高级别子宫颈鳞状上皮内病变经不同手术治疗的效果及术后复发危险因素

高级别子宫颈鳞状上皮内病变经不同手术治疗的效果及术后复发危险因素

高级别子宫颈鳞状上皮内病变经不同手术治疗的效果及术后复发危险因素封媛媛①【摘要】目的:探讨子宫颈冷刀锥切术(CKC)和子宫颈环形电切术(LEEP)治疗高级别子宫颈鳞状上皮内病变(SIL)效果,同时分析切缘阳性和复发的独立危险因素。

方法:回顾性分析本院2015年1月-2018年12月收治高级别SIL患者共613例临床资料,其中330例采用CKC术治疗设为A组,283例采用LEEP术治疗设为B组。

比较两组手术时间、术中出血量、切缘阳性率及腺体累及率,采用Cox回归模型分析切缘阳性和复发独立危险因素。

结果:B组手术时间和术中出血量均显著少于人组(P<0.05);多因素分析结果显示,绝经、病灶范围及阴道镜检查结果均是患者术后切缘阳性独立危险因素(P<0.05);多因素分析结果显示,切缘阳性、绝经及H P V感染均是患者术后复发独立危险因素(P<0.05)结论:相较于CKC,LEEP治疗SIL可有效缩短手术时间,减轻手术创伤;绝经、病灶范围及阴道镜检查结果与术后切缘阳性独立相关,切缘阳性、绝经及HPV感染均是患者术后复发独立危险因素。

【关键词】子宫颈冷刀锥切术子宫颈环形电切术子宫颈鳞状上皮内病变切缘复发doi:10.14033/ki.cfmr.2021.07.002文献标识码A文章编号1674-6805(2021)07-0003-04Clinical Efficacy of Different Surgical Treatments for High-Grade Cervical Squamous Intraepithelial Lesions and Risk Factors of Postoperative Recurrence/FENG Yuanyuan.//Chinese and Foreign Medical Research,2021,19(7):3-6[Abstract]Objective:To investigate the clinical efficacy of different surgical treatments of cold knife coning of cervix(CKC)and loop electro-excisional procedure(LEEP)for high-grade cervical squamous intraepithelial lesions(SIL)and risk factors for positive margin and postoperative recurrence.Method:Clinical data of613patients with high grade SIL in our hospital from January2015to December2018were retrospectively selected,330patients treated with CKC were set as the group A,283patients treated with LEEP were set as the group B.The operation time,intraoperative blood loss,positive rate of incision margin and gland involvement rate were compared between the two groups.Cox regression model was used to analyze the independent risk factors of positive margin and postoperative recurrence. Result:The operation time and intraoperative blood loss in the group B were significantly less than those in the group A(P<0.05).Multivariate analysis showed that menopause,scope of lesions and colposcopy results were independent risk factors for positive margins(P<0.05).Multivariate analysis showed that positive margin, menopause and HPV infection were independent risk factors for postoperative recurrence(P<0.05).Conclusion:Compared with CKC,LEEP treatment of high-grade SIL can effectively shorten the operation time and reduce the surgical trauma.At the same time,menopause,scope of lesions and colposcopy results were independently related to the postoperative positive margin,while the positive margin,menopause and HPV infection were independent risk factors for postoperative recurrence.[Key words]Cold knife coning of cervix Loop electro-excisional procedure Squamous intraepithelial lesions Margin RecurrenceFirst-author's address:The Fifth People's Hospital of Datong City,Datong037009,China①大同市第五人民医院山西大同037009流变学指标,并且比起单纯采用胺碘酮治疗,该治疗方式见效更快,且用药安全性高。

精神分裂症患者经利培酮结合MECT治疗的效果评价

精神分裂症患者经利培酮结合MECT治疗的效果评价

临床医药文献杂志Journal of Clinical Medical 2018 年第 5 卷第 8 期2018 Vol.5 No.8124精神分裂症患者经利培酮结合MECT治疗的效果评价符夏瑜(海南省安宁医院,海南海口 570206)【摘要】目的 探析精神分裂症患者经利培酮结合MECT(改良电抽搐)疗效。

方法 选取我院2015年7月~2017年7月精神科收治的精神分裂症患者72例作为对象,依照随机分组方式,分为研究组、对照组,对照组予以利培酮治疗,研究组实行利培酮结合MECT治疗,比对两组治疗前后疗效。

结果 治疗后,研究组BPRS量表评分与对照组相比,显著较低,数据差异有统计学意义(P<0.05)。

结论 精神分裂症患者经利培酮结合MECT治疗后,可有效改善患者精神分裂等症状,稳定患者病情,可推广。

【关键词】精神分裂症;利培酮;MECT;疗效【中图分类号】R749.3 【文献标识码】B 【文章编号】ISSN.2095-8242.2018.8.124.02精神分裂症属于严重的精神疾病,其致病因素较为复杂,当前临床仍未明确其病因,且疾病的病程较长、病情易反复,不仅会损害患者社会功能,还会极大程度上降低患者生活质量,给患者家庭带来巨大经济压力[1]。

临床治疗该疾病时,大多以药物治疗为主,因此本研究重点探究精神分裂症患者经利培酮结合MECT(改良电抽搐)治疗的效果,数据结果归整如下。

1 资料与方法1.1 一般资料选取我院2015年7月~2017年7月精神科收治的精神分裂症患者72例作为对象,随机将其划分为两组,分别为研究组、对照组,研究组(36例),男20例,女16例,年龄24~70岁,平均年龄(35.68±2.67)岁,病程7个月~10年,平均病程(2.52±1.25)年;对照组(36例),男21例,女15例,年龄22~71岁,平均年龄(36.51±3.41)岁,病程6个月~11年,平均病程(2.67±0.97)年。

international journal of clinical practice影响因子

international journal of clinical practice影响因子

international journal of clinical practice影响因子International Journal of Clinical Practice(IJCP)是一本涵盖临床医学领域的国际性期刊,它始刊于1996年,由约翰·维立克(John Wiley)公司出版。

它的影响因子(impact factor)是衡量期刊影响力的重要指标之一,可以反映该期刊在学术界中的重要性和被引用的频率。

首先,影响因子的定义是在某一特定年度,过去两年内该期刊发表的论文在该年被引用的次数与过去两年该期刊发表的论文总数的比值。

因此,影响因子可以反映该期刊在学术界中被引用的频率和该期刊的论文质量。

其次,对于International Journal of Clinical Practice(IJCP)这个期刊而言,其影响因子是根据该期刊发表的文章在学术界中的被引频率来计算的。

因为该期刊是一个国际性的期刊,它吸引了来自世界各地的研究人员和学者提交的高质量研究成果。

这样的特点使得该期刊的影响因子较高。

此外,International Journal of Clinical Practice(IJCP)是一本对临床医学领域的多个子领域感兴趣的读者具有独特吸引力的期刊。

它涵盖了内科学、外科学、儿科学、妇产科学、神经科学、精神病学等多个领域,展示了来自世界各地的新发现、研究成果和临床实践经验。

这些研究和实践成果对临床医学的发展和进步具有重要影响。

因此,该期刊的影响因子在学术界受到广泛认可。

另外,International Journal of Clinical Practice(IJCP)对于学术界的重要性还表现在以下几个方面。

首先,该期刊注重发表高质量的原创研究和临床实践经验,促进了临床医学领域的学术交流和知识的共享。

其次,该期刊还为医学研究人员提供了一个交流和讨论的平台,有助于推动临床医学领域的研究和实践发展。

体外诊断领域的英文综述

体外诊断领域的英文综述

体外诊断领域的英文综述The field of in vitro diagnostics, commonly referred to as IVD, encompasses a wide range of medical tests and devices that are performed outside of the body to aid in the diagnosis, monitoring, and management of various diseases and conditions. In vitro diagnostics include tests conducted on samples such as blood, urine, saliva, and tissue, and are essential for providing accurate and timely information to healthcare professionals.In recent years, there have been significant advancements in the field of in vitro diagnostics, with the development of new technologies and the introduction of innovative testing methods. These advancements have led to improvements in the accuracy, speed, and reliability of diagnostic tests, ultimately enhancing patient care and outcomes.One key area of focus in the field of in vitro diagnostics is the development of point-of-care testing,which allows for rapid and convenient testing at the bedside or in other clinical settings. This has the potential to improve patient management by enabling quick decision-making and timely initiation of treatment.Furthermore, the integration of molecular diagnostics into in vitro testing has revolutionized the way certain diseases are diagnosed and managed. Techniques such as polymerase chain reaction (PCR) and next-generation sequencing have enabled the detection of genetic and molecular markers, leading to more personalized and targeted treatment approaches.In addition, the field of in vitro diagnostics plays a crucial role in infectious disease testing, cancer screening, and monitoring of chronic conditions such as diabetes and cardiovascular disease. The continuous evolution of diagnostic technologies and the increasing availability of biomarkers and novel testing platforms are driving the expansion and diversification of in vitro diagnostics.Overall, the field of in vitro diagnostics continues to be a dynamic and rapidly evolving area of healthcare, with ongoing research and development efforts aimed at further enhancing the performance and utility of diagnostic tests for the benefit of patients and healthcare providers.。

耳穴压丸治疗1例视网膜中央动脉阻塞患者失眠的护理体会

耳穴压丸治疗1例视网膜中央动脉阻塞患者失眠的护理体会

中西医结合护理Chinese Journal of Integrative Nursing2023 年第 9 卷第 4 期Vol.9, No.4, 2023耳穴压丸治疗1例视网膜中央动脉阻塞患者失眠的护理体会耿丽娜, 杨剑英, 王璐霞, 李娜(中国中医科学院眼科医院 眼科门诊, 北京, 100040)摘要: 本文总结1例采用耳穴压丸治疗视网膜中央动脉阻塞(CRAO )后失眠的护理经验。

在完善护理评估的基础上,采用中医耳穴压丸治疗,同时积极配合医生进行救治,遵医嘱及时给予安全的氧疗护理,加强患者的心理护理和饮食护理,有助于缓解患者心理压力,改善睡眠质量。

关键词: 视网膜中央动脉阻塞; 氧疗; 耳穴压丸; 失眠; 中医护理中图分类号: R 473.77 文献标志码: A 文章编号: 2709-1961(2023)04-0166-04Auricular acupoint pressing therapy andnursing management for insomnia in a patient withcentral retinal artery occlusionGENG Lina ,YANG Jianying ,WANG Luxia ,LI Na(Ophthalmic Clinic , Ophthalmic Hospital of Chinese Academy of Traditional Chinese Medicine , Beijing , 100040)ABSTRACT : This paper summarized the auricular acupoint pressing therapy an nursing measures for insomnia in a patient with central retinal artery occlusion. On the basis of nursing risk assess⁃ment , Traditional Chinese Medicine auricular acupoint pressing therapy was adopted. Comprehen⁃sive nursing interventions such as strengthening cooperation between medical and nursing care , providing oxygen therapy according to the doctor's advice , enhancing the psychological care and diet care of patients were carried out during the treatment. Traditional Chinese Medicine auricular acupoint pressing therapy can effectively relieve the psychological stress and improve the sleep quality of the patient.KEY WORDS : central retinal artery occlusion ; oxygen therapy ; auricular acupoint pressing therapy ; insomnia ; Traditional Chinese Medicine nursing 视网膜中央动脉阻塞(CRAO )是指视网膜中央动脉因某些因素而出现动脉血流运行不畅,甚至中断,如动脉痉挛、低灌注、血液黏稠度升高、栓塞及栓子的形成等,导致动脉血流中断,从而导致视网膜组织缺血和缺氧,进而出现组织变性和坏死的一种严重的致盲性眼科急危重症[1]。

journal of clinical investation submit

journal of clinical investation submit

Journal of Clinical Investigation是临床研究领域的知名学术期刊,提交论文的步骤如下:
1.准备论文:确保您的论文符合Journal of Clinical Investigation的稿件要求,包括研究问题、方法、结果和结论等内容。

2.在线提交:访问Journal of Clinical Investigation的官方网站,并按照网站上的指导进行在线提交。

您需要填写论文的基本信息,上传稿件,
并支付相应的稿件处理费用。

3.等待审稿:稿件将由编辑委员会进行审稿,审稿过程可能需要一段时间。

您可以通过官方网站查看稿件状态。

4.接受或拒绝:根据审稿人的意见,您可能会收到稿件被接受或拒绝的通知。

如果稿件被接受,您需要按照编辑的要求修改稿件,并在规定时间内
完成修改。

5.最终编辑和发表:经过最终编辑和校对后,您的论文将被发表在Journal of Clinical Investigation上。

需要注意的是,提交论文需要符合Journal of Clinical Investigation的投稿指南和要求,并遵守相应的伦理和法律规范。

如果您不确定自己的论文是否符合要求,可以向期刊编辑咨询或寻求专业人士的建议。

识别和降低研究用新药在首次人体和早期临床试验中风险的策略指导原则(三)

识别和降低研究用新药在首次人体和早期临床试验中风险的策略指导原则(三)

识别和降低研究用新药在首次人体和早期临床试验中风险的策略指导原则(三)欧洲药品管理局人用医药产品委员会(2017年7月更新)(吴宇佳 译 陈菡菁 校 李雪宁 审校)译者按在新药研发的生命周期中,首次人体(first-in-human, FIH)和早期临床试验(clinical trials, CT)作为从体外到体内的过渡研究至关重要,安全性是早期CT关注的重点。

2016年1月,法国雷恩市的一项FIH临床试验中,1名受试者由于服用高剂量试验药品死亡。

为避免类似情况的发生,并且考虑到CT设计近年的发展,欧洲药品监督管理局人用医药产品委员会于2017年7月20日发布了更新版本的《识别和降低研究用新药在首次人体和早期临床试验中风险的策略指导原则》。

本文为该指导原则的中文译本,由复旦大学附属中山医院临床药理研究室吴宇佳翻译、陈菡菁校对、李雪宁教授审校。

第三部分介绍了早期CT的计划和实施,包括方案设计中应注意的问题、申办方和研究者的职责以及研究中心的设施和人员要求,相较于旧版本增加了综合方案(integrated protocol)设计时应注意的问题。

研究方案是CT执行过程中最重要的文件之一,申办方应在研究方案中准确描述试验中的操作以及关键决策的原理等。

该指导原则正式英文版请见:https://www.ema.europa.eu。

(续前)8 FIH和早期CT的计划和实施8.1 一般考虑试验的设计应能充分利用从研究中获得的信息,在不会纳入过多的受试者的同时,确保受试者的安全。

总体研究设计应证明每个研究部分是合理的,还要充分考虑每个研究将提供的数据和可用于综合评估的时间。

不可为了获取数据的速度或一些流程上的原因而忽视安全性的考虑。

降低风险的举措应与其不确定性和潜在风险相匹配。

设计研究时的关键要素包括:1)研究人群的选择(参考第8.2.3部分)。

2)首剂/起始剂量、最大剂量、最大暴露量、最大治疗时间(参考第7部分)。

住院患者认知障碍识别和信息管理的整合性综述

住院患者认知障碍识别和信息管理的整合性综述

住院患者认知障碍识别和信息管理的整合性综述熊蓓蓓;Daniel X.Bailey;Paul Prudon;Elaine M.Pascoe;Leonard C.Gray;Frederick Graham;Amanda Henderson;Melinda Martin-Khan【期刊名称】《International Journal of Nursing Sciences》【年(卷),期】2024(11)1【摘要】目的旨在对目前提供急性照护的医院识别认知障碍患者以及在病历中记录和管理认知相关信息的实际情况及政策要求和推荐方法进行综述。

方法采用Whittemore和Knaf1的五步法,系统检索Medline,CINAHL和Scopus数据库,并检索了灰色文献来源。

纳人了提供急性照护的医院已实施的患者认知障碍识别和认知信息管理相关的文献。

采用混合方法评价工具和灰色文献质量评估清单对文章质量进行评价。

采用主题分析法呈现和整合结果。

该综述已在PROSPERO预注册(CRD42022343577)。

结果共22篇原始研究文献和10篇政府/行业文件被纳人分析。

结果显示,实践和政策之间存在差距。

尽管在政策层面上高度重视认知障碍的识别、认知相关信息的透明度,以及与患者、家属和照顾者(如适用)之间的互动,但有时在临床实践中,认知评估是非正式的,患者的认知相关信息未作记录,与患者、家属和照顾者的互动也存在不足。

结论.通过整合认知评估,利用信息技术开发信息管理综合系统,建立相关法律法规,提供教育与和培训,并采用国家层面的策略,有可能显著改善对认知障碍患者的识别和护理。

【总页数】13页(P120-132)【作者】熊蓓蓓;Daniel X.Bailey;Paul Prudon;Elaine M.Pascoe;LeonardC.Gray;Frederick Graham;Amanda Henderson;Melinda Martin-Khan【作者单位】Centre for Health Services Research of Medicine University of Queensland;Centre for Clinical Research of Medicine University of Queensland Bris bane&Women’s Hospital;Dementia and Delirium of Medicine Alexandra Hospital;School of Nursing of Health University of Technology;Nursing Practice Development Unit Alexandra Hospital;School of Nursing and Social Sciences Queensland University;Griffith Health University;School of Nursing and Paramedicine University of the Sunshine Coast;Department of Health and Life Sciences of Exeter Kingdom;School of Nursing of Northern British Columbia George【正文语种】中文【中图分类】R47【相关文献】1.轻度认知障碍早期识别对老年住院患者安全隐患事件的影响分析2.运动结合认知训练在轻度认知障碍和阿尔茨海默病患者中应用的整合性综述3.痴呆症患者家庭照顾者实施在线教育项目的挑战:整合性综述4.促进慢性阻塞性肺疾病哮喘患者自我监控空气质量的护理干预措施: 整合性综述5.肝细胞癌患者的症状和症状群及常用工具的整合性综述因版权原因,仅展示原文概要,查看原文内容请购买。

european journal of clinical investigation投稿经验

european journal of clinical investigation投稿经验

european journal of clinical investigation投稿经验
作为一个对话型AI助手,我没有真实的经验或个人观点。

但是,我可以向您提供一些关于European Journal of Clinical Investigation投稿经验的常见建议。

- 在投稿前,仔细阅读期刊的投稿指南和要求,并按照要求准
备您的稿件。

平均来说,在撰写一篇学术论文之前,最好熟悉目标期刊的写作和格式要求。

- 确保您的研究问题和结论与该期刊的范围和目标读者群相关。

阅读一些已经发表在该期刊上的文章,以了解其对特定领域的研究问题和方法的兴趣。

- 确保您的论文具有足够的原创性和科学价值。

提供清晰的研
究问题、方法、结果和讨论,以便读者能够理解和验证您的研究。

- 如果您的论文涉及人类或动物的实验研究,请确保您遵守伦
理审查机构的要求,并在论文中提供相应的信息。

- 在投稿前,最好将您的论文进行同行评审。

请向其他专家和
同事寻求他们的反馈,以提高您的研究质量。

- 在投稿时,认真填写所有必要的信息,并准备好您的原始数
据和研究材料,以备编辑和同行评审使用。

请注意,以上建议仅供参考。

每个期刊都有自己的投稿流程和
要求,因此最好查看European Journal of Clinical Investigation 的投稿指南以获取最准确和最新的信息。

肌电图导引下局部肌内注射A型肉毒毒素治疗脑卒中后肢体痉挛的临床疗效

肌电图导引下局部肌内注射A型肉毒毒素治疗脑卒中后肢体痉挛的临床疗效

DOI: 10.12022/jnnr.2018-0103肌电图导引下局部肌内注射A 型肉毒毒素治疗脑卒中后肢体痉挛的临床疗效常悦悦,余传庆,张 梅,丁 芳淮南市第一人民医院神经内科,安徽 淮南 232007CONFLICT OF INTEREST: The authors have no conflict of interest to disclose.Received November 13, 2018; accepted for publication February 28, 2019Copyright © 2019 by Journal of Neurology and Neurorehabilitation通信作者余传庆E-MAILyuchuanqin1967@摘要 目的:探讨肌电图导引下局部肌内注射A 型肉毒毒素治疗脑卒中后肢体痉挛的疗效。

方法:研究对象为96例脑卒中后痉挛性偏瘫患者,按照痉挛程度较为严重的上肢或下肢的Fugl-Meyer 评定(Fugl-Meyer Assessment ,FMA )量表评分结果,分为上肢A 组(26例,≥51分)、B 组(21例,34~50分)和C 组(9例,≤33分)以及下肢A 组(25例,≥23分)、B 组(12例,17~22分)和C 组(3例,≤16分)。

在肌电图导引下确定治疗靶肌肉,进行局部肌内注射A 型肉毒毒素治疗(1次多点注射,每一例患者的总注射剂量≤400 U ),并配合肢体功能训练。

在治疗后1个月、3个月和6个月,采用改良Ashworth 量表、FMA 量表、改良Barthel 指数、世界卫生组织生存质量测定量表、抑郁自评量表、焦虑自评量表和肌电图评估疗效。

结果:治疗后1个月、3个月和6个月,上肢A 组FAM 量表评分分别为60.35士1.51、62.35士3.01和64.10士2.56,B 组FAM 量表评分分别为39.10士2.23、42.12士2.34和43.09士1.89;下肢A 组FAM 量表评分分别为33.16士1.06、33.45士2.14和33.89士2.08,B 组FAM 量表评分分别为20.95士3.75、23.45士2.20和24.12士1.97。

《2022年原发性中枢神经系统淋巴瘤治疗中国专家循证共识》解读

《2022年原发性中枢神经系统淋巴瘤治疗中国专家循证共识》解读

㊃共识解读㊃[收稿日期]2023-03-10[作者简介]河北省卫生厅指导性计划(Z D 20140222)[作者简介]赵煜微(1998-),女,新疆乌鲁木齐人,河北大学附属医院医学硕士研究生,从事淋巴瘤疾病诊治研究㊂*通信作者㊂E -m a i l :y o u c h a o ji a 1@163.c o m ‘2022年原发性中枢神经系统淋巴瘤治疗中国专家循证共识“解读赵煜微,刘清云,贾友超*(河北大学附属医院肿瘤内科,河北省肿瘤放化疗机制与规程研究重点实验室,河北保定071000) [摘要] 原发性中枢神经系统淋巴瘤(p r i m a r y C N S l y m p h o m a ,P C N S L )是一种结外非霍奇金淋巴瘤,占新诊断的中枢神经系统肿瘤的3%~4%㊂针对P C N S L 的诊断及治疗,中华医学会神经外科分会和中国抗癌协会血液肿瘤专业委员会组成多学科专家组,在循证医学的指导下达成共识㊂本共识在诊断方面主要涉及影像学检查㊁术前皮质类固醇应用㊁病理活组织检查㊁认知功能评估等;在治疗方面,对诱导治疗㊁巩固治疗及复发/难治患者治疗等提出了建议,推动更加规范㊁有效㊁安全的治疗的发展㊂[关键词] 神经淋巴瘤;诊断;治疗 d o i :10.3969/j.i s s n .1007-3205.2023.12.001 [中图分类号] R 735.7 [文献标志码] A [文章编号] 1007-3205(2023)12-1365-05原发性中枢神经系统淋巴瘤(p r i m a r y CN S l y m p h o m a ,P C N S L )是一种罕见的结外非霍奇金淋巴瘤,常累及中枢神经的各个方面,包括大脑㊁脊髓㊁脑脊液㊁颅神经和脊神经,以及眼睛[1]㊂由于95%P C N S L 的病理类型为弥漫性大B 细胞淋巴瘤(d i f f u s e l a r g eB c e l l l y m ph o m a ,D L B C L ),故本共识仅侧重于P C N S L -D L B C L s ㊂本共识阐述的P C N S L中还包含原发性眼内淋巴瘤(p r i m a r y vi t r e o r e t i n a l l y m p h o m a ,P V R L )[2]㊂与‘中国临床肿瘤学会(C h i n e s eS o c i e t y o fC l i n i c a lO n c o l o g y,C S C O )淋巴瘤诊疗指南2022“不同[3],本专家共识更加强调影像学检查㊁术前皮质类固醇应用㊁病理活组织检查(活检)㊁认知功能评估等几个方面,对诱导治疗㊁巩固治疗及难治/复发患者治疗等进行了完善和补充[2]㊂1 诊 断根据中枢神经系统相关临床表现结合头颅磁共振成像(m a g n e t i c r e s o n a n c e i m a g i n g,M R I )[增强及弥散加权技术(d i f f u s i o n w e i g h t e d i m a g i n g,DW I )],来诊断和评估是否为P C N S L ㊂对于疑似P C N S L 患者,病理组织可通过多模态断层扫描引导活检或微创手术的方式来获取(2C )[2]㊂由于病理活检为肿瘤诊断的 金标准 ,为保证诊断的准确性,如果患者身体状况允许,尽可能在活检前停用或不使用皮质类固醇药物(1C )[2]㊂对于疑似P V R L 患者,病理组织可通过玻璃体活检来获取(2D )[2],如果患者身体状况允许,建议至少在活检前2周停用皮质类固醇药物(2D )[2]㊂病理诊断为淋巴瘤的患者需要进行进一步全面评估,包括一般情况评估[病史采集㊁查体㊁体力状况评分㊁认知功能评估(2B )㊁器官功能评价㊁活动性感染筛查等]和肿瘤相关评估[头颅增强M R I㊁正电子发射计算机断层显像(p o s i t r o ne m i s s i o n t o m o g r a p h y ,P E T )/计算机断层显像(c o m p u t e dt o m o g r a p h y,C T )㊁脑脊液检查㊁骨髓活检,脊髓M R I 等],如果肿瘤侵犯眼部还需对眼部情况进行评估(裂隙灯㊁眼底镜㊁眼超声㊁光学相干断层扫描等)[2]㊂在影像学方面,对治疗前的患者优先选择头颅增强M R I 来明确病变所在的位置㊁大小和形状;对无法应用造影剂患者可选用常规核磁;对系统分期及疑似复发患者可选用全身P E T -C T 来进行评估[3]㊂虽然P E T -C T 与颅脑增强M R I 都能够区分大多数胶质母细胞瘤㊁转移性脑肿瘤与P C N S L ,但对于18氟-氟代脱氧葡萄糖及L -11碳-甲基-蛋氨酸摄取的视觉分析却无助于发现非典型P C N S L 病灶[4]㊂所以本共识推荐使用M R I (增强和DW I )来诊断和评估P C N S L 患者(1B )[2]㊂脑部恶性肿瘤在M R I 上常表现为DW I 高信号,表观弥散系数低信号;但当部分肿瘤病灶形态学特点不典型时,M R I㊃5631㊃第44卷第12期2023年12月河北医科大学学报J O U R N A L O F H E B E I M E D I C A L U N I V E R S I T YV o l .44 N o .12 D e c . 2023无法作出诊断[4-5]㊂P E T-C T中传统参数及代谢参数可为鉴别诊断提供信息,这有助于提高诊断的准确性[5]㊂在治疗后的随访中,P E T-C T能较早发现肿瘤的复发及转移[6]㊂综上,本共识推荐在特定时间点,如初诊或复发时使用全身P E T-C T进行评估(2B)[2]㊂由于P C N S L肿瘤为多灶性㊁浸润性生长,肿瘤范围可能超出影像学可见区域,故进行活检或微创手术的目的是为了获取病理样本㊁作出诊断,而非减少肿瘤细胞数量[7]㊂尽管开颅手术较细针穿刺活检能获得更大的组织样本,增加诊断的准确性,但由于肿瘤为多发病变(65%~70%)且多分布于脑室周围或脑深部白质区域,这会增加手术难度且容易影响患者神经功能[8-9]㊂故本共识建议通过多模态断层扫描引导活检或微创手术的方式获取病理样本(2C)[2]㊂对浅表单发病变且术后神经系统功能维持较好(风险等级评估为低风险)的患者,可行全切除手术来获取样本[7,9]㊂对大面积占位性病变且伴有急性脑疝症状的患者可通过手术切除的方式来获取肿瘤样本,这种方式不但可以获取足量样本,也可迅速改善患者症状,增加药物治疗时间窗[7,9]㊂其余患者特别是深部病变或多发病变的患者则更建议采用多模态断层扫描引导活检或微创手术来获取样本㊂与其他中枢神经系统肿瘤相似,P C N S L患者在进行手术治疗前也需要充分的术前评估,了解患者身体状况,减少不良事件的发生率[7]㊂本共识进一步规范了术前皮质类固醇药物的使用㊂因为肿瘤诊断出现假阴性的概率会随着皮质类固醇的应用时长的增加而增加,且肿瘤本身对于皮质类固醇药物敏感,在术前应用皮质类固醇会增加手术结果的不确定性[8-10]㊂有研究结果显示,在术前应用及不应用皮质类固醇药物的患者中,术后不能明确诊断的例数分别占总例数的10.3%和3.4%[9]㊂所以对于P C N S L患者,如果患者身体状况允许活检前推荐不使用或停用皮质类固醇药物(1C)[2]㊂对于P V R L患者,则推荐至少停药2周(2D)[2]㊂在本共识中特别强调了认知功能评估在治疗全程中的作用㊂肿瘤的治疗不仅需要关注肿瘤本身,还需要关注患者的身体㊁心理及社会功能㊂由于肿瘤位置的特殊性,肿瘤的进展㊁治疗等过程都会影响患者的认知功能和生活质量,故需在治疗全程对患者的认知功能和生活质量进行评价[10]㊂利用认知功能评价工具将患者的认知状态及生活质量以数字形式展现出来,更直观地显示各治疗方式对于患者的影响㊂简易精神状态检查量表(m i n i-m e n t a l s t a t e e x a m i n a t i o n,MM S E)操作简单㊁内容全面,是目前最广泛使用的认知筛查测试工具㊂但因其天花板效应和有限的动态表现范围,在轻度认知障碍鉴别等方面并不如蒙特利尔认知评估(M o n t r e a l c o g n i t i v e a s s e s s m e n t,M o C A)准确[11]㊂欧洲癌症研究与治疗组织(T h eE u r o p e a nO r g a n i z a t i o n f o rR e s e a r c ha n d T r e a t m e n t o fC a n c e r,E O R T C)生活质量问卷包括癌症患者生活㊁情感㊁社会健康问题,对癌症患者生活质量的评估既具有普遍性,又具有特异性[12]㊂本共识推荐利用MM S E和M o C A来评估患者认知功能;利用E O R T C生活质量问卷来评估患者的生活质量(2B)[2]㊂2治疗中枢神经系统(c e n t r a ln e r v o u ss y s t e m,C N S)的血脑屏障(b l o o d-b r a i nb a r r i e r,B B B)通过调节神经血管单元来维持C N S稳态,保障大脑功能的正常运转,然而这种功能也阻碍了全身化疗药物向中枢的输送[13]㊂因此,对于P C N S L的治疗药物的选择需要考虑B B B的影响㊂对于新诊断P C N S L的患者首先通过诱导治疗降低肿瘤负荷,进一步进行巩固治疗来消灭诱导治疗后残留的肿瘤细胞㊂2.1诱导治疗根据目前的研究结果显示大剂量甲氨蝶呤(h i g h-d o s em e t h o t r e x a t e,H D-MT X)对于治疗P C N S L有效,故优先推荐以H D-MT X为基础,联合应用利妥昔单抗(2C)㊁阿糖胞苷(2B)㊁替莫唑胺(2C)或其他可以穿过血脑屏障的药物(2C)的方案进行治疗(1B)[2]㊂而对于对化疗药物耐受性较差的患者,推荐采用W B R T或减量MT X+ W B R T;对于肿瘤侵犯眼部的患者推荐局部(眼部)放化疗联合全身治疗(2C)[2]㊂中枢神经系统中的MT X药物浓度受到静脉输注的药物剂量及输注速率的影响[14]㊂当MT X剂量达到1~8g/m2时,药物可以进入中枢神经系统;当MT Xȡ3g/m2且超过3h时,药物在中枢神经系统中可以达到细胞毒性水平[15]㊂欧洲神经肿瘤学会最新推荐:MT X输注时间为2~3h,且在治疗前后需通过充分补液㊁尿液碱化㊁亚叶酸钙解救及MT X浓度监测等方式来保证患者用药安全,避免粒细胞减少㊁肝肾功能损伤等不良反应的发生[14-15]㊂在诱导治疗阶段,患者需要接受4~6个周期的治疗,为保证疗效,每周期时间间隔不应超过2~3周[15]㊂MT X主要通过肾脏排泄(70%~ 90%),长期持续暴露于低浓度MT X下可引起骨髓㊃6631㊃河北医科大学学报第44卷第12期抑制及其他严重的毒性反应[16]㊂故当患者肌酐清除率<30m L/m i n时,不建议使用H D-MT X方案进行治疗[15]㊂在肾功能正常的患者中,MT X的清除速率也存在很大的个体差异,主要取决于剂量㊁年龄和输注时间[16]㊂故在临床实践中,当患者年龄ȡ60岁时,不考虑应用H D-MT X进行治疗,但这一临界值是根据经验判断形成的,没有明确的证据支持[2,17]㊂P C N S L的发病率随年龄的增加而增加,近一半的患者年龄ȡ60岁,英国专家建议对于老年患者治疗方案的选择需要对患者总体状况进行评估,特别是心脏和肾功能[17]㊂在31例(100%)年龄ȡ70岁的患者中,应用H D-MT X,总缓解率为96.7%,其中完全缓解(c o m p l e t e r e s p o n s e,C R)率为60%,部分缓解(p a r t i a l r e s p o n s e,P R)率为36.7%;无进展生存期(p r o g r e s s f r e e s u r v i v a l,P F S)和总生存期(o v e r a l ls u r v i v a l,O S)分别为7.1个月和37个月[18];其中27例患者(87%)观察到了MT X相关毒性(74.1%为Ⅰ/Ⅱ级,9.7%为Ⅲ/Ⅳ级),仅4例(12.9%)因毒性终止治疗[16]㊂综上所述,H D-MT X 在治疗老年P C N S L患者中显示出良好的疗效,并且耐受良好[16]㊂故对于老年P C N S L患者的治疗应充分评估患者总体状况,制定个体化的治疗方案㊂增加利妥昔单抗对于B细胞非霍奇金淋巴瘤的治疗具有较好的疗效及安全性㊂但因利妥昔单抗分子量较大,通过血脑屏障受阻,导致其在脑脊液药物浓度仅为血清药物浓度的0.1%[19-20]㊂较低浓度的利妥昔单抗似乎无法达到治疗的目的,但在新诊断的P C N S L-D L B C L患者中使用却显示出一定的疗效㊂一项随机Ⅱ期试验(I E L S G32)中显示对于新诊断的P C N S L-D L B C L患者加用利妥昔单抗,客观缓解率(o b j e c t i v e r e s p o n s e r a t e,O R R)㊁P F S㊁O S都有明显改善[21]㊂另一项研究数据表明加用利妥昔单抗可以增加C R率[22]㊂这些结果产生可能是由于肿瘤的生长压迫及相关细胞因子的释放,改变了B B B的通透性[13]㊂I w a m o t o等[20]利用放射性物质破坏B B B,在复发/难治患者的治疗中,加用C D20单抗中位P F S为6.8周,O S为14.3周㊂加用利妥昔单抗不仅可以改善预后,而且其本身不良反应少,联合用药并没有增加严重并发症的发生率[19,21]㊂在P C N S L治疗中加用利妥昔单抗有一定的安全性及疗效,但B B B的存在限制了利妥昔单抗发挥作用㊂本共识推荐对新诊断的P C N S L-D L B C L患者可以在诱导治疗中使用包含利妥昔单抗的方案进行治疗(2C)[2]㊂一项对31项研究进行荟萃分析的研究[22]显示H D-MT X与其他化疗药物联用可提高肿瘤对H D-MT X的敏感度,增加C R率,且对于联合化疗药物的选择有如下建议:①推荐选择有高质量临床研究作为依据的药物(保证药物的安全性及可行性)㊂②推荐选择能够穿透B B B的药物(避免B B B削减药物疗效)㊂故本共识推荐联合阿糖胞苷(2B)㊁替莫唑胺(2C),或其他可以穿透B B B(2C)的药物[2]㊂2.2巩固治疗在一项Ⅱ临床试验中显示在18~ 60岁的P C N S L患者中分别应用自体干细胞移植(a u t o l o g o u s s t e m-c e l l t r a n s p l a n t a t i o n,A S C T)和非减低剂量全脑放疗(w h o l eb r a i nr a d i a t i o n t h e r a p y, W B R T),8年P F S分别为67%和39%[23]㊂应用W B R T治疗的患者在治疗后出现明显的平衡及认知功能的下降,且与A S C T相比容易复发,应避免在一线治疗中使用;而应用A S C T的患者不但记忆力及生活质量得到明显改善,而且在预防复发方面似乎有效[23]㊂尽管A S C T可以改善患者症状及提高生活质量,但其在治疗过程中存在的血液毒性是导致A S C T患者死亡的重要因素之一[23]㊂巩固治疗的选择不但需要考虑疾病复发,还需考虑患者治疗后的生存质量,相较于W B R T,本共识推荐使用A S C T作为巩固治疗(2C)[2]㊂对于不适合预处理化疗的患者似乎非清髓巩固化疗也是一个不错的选择㊂根据一项Ⅱ期临床试验(C A L G B51101)显示A S C T组与非清髓巩固化疗[依托泊苷加大剂量阿糖胞苷(H D-A r a c)]相比,3年O S相近,分别为83%和72%,差异无统计学意义[24]㊂但是非清髓巩固化疗可行性㊁耐受性等相关结论尚未公布,还需等待进一步的数据来明确治疗效果㊂2.3复发/难治的患者治疗可根据患者体能状态㊁合并症㊁缓解持续时间及既往治疗方案来选择治疗方法㊂对于伴有重度合并症和化疗禁忌证的患者一般推荐采用姑息治疗或临床试验[15]㊂对于既往使用H D-MT X有效且使用W B R T/A S C T进行巩固的患者,根据最后一次应用MT X的时间来选择治疗方案㊂如果时间间隔ȡ1年,建议使用H D-MT X联合治疗;如果时间间隔<1年,本共识建议可使用伊布替尼(i b r u t i n i b)联合或不联合大剂量化疗作为再诱导治疗的方法(2C)[2,15]㊂既往只应用H D-MT X治疗且有效的患者,年龄<65岁且体能状态良好,推荐选择A S C T进行治疗[2,15]㊂对于复发病变有限且化疗无效的患者建议采用立体定向放射外科治疗(2D)[2]㊂既往MT X敏感的患者,当疾病复发时,应用㊃7631㊃河北医科大学学报第44卷第12期MT X依旧敏感且能产生新的客观缓解率[25]㊂根据C a o等[25]的研究结果显示对于既往使用MT X化疗有效的患者,当疾病复发后,再次接受MT X化疗, O R R为85%(75%患者C R,10%患者P R,15%患者疾病进展)㊂并且对于可耐受MT X化疗的患者,再次应用MT X安全性也能得到一定的保证[25]㊂布鲁顿酪氨酸激酶抑制剂不但可以抑制B细胞恶性肿瘤的发生发展,还可以快速穿透B B B[26]㊂在一项前瞻性多中心Ⅱ期复发或难治性(R/R) P C N S L研究中显示:应用伊布替尼(560m g/d)两个月后患者的疾病控制率为70%,其中C R占19%,P R占33%,疾病稳定占10%;中位P F S为4.8个月(95%C I:2.8~12.7),O S为19.2个月(95%C I:7.2~N R)[27]㊂目前在P C N S L的治疗上,还存在一些新药的研究,例如C A R-T㊁P I3K/m T O R抑制剂㊁免疫检查点抑制剂等㊂这些药物的使用都显示出了一定的疗效,但在剂量㊁应用人群㊁作用机制及不良反应等方面还需要进一步观察㊂综上所述,P C N S L的治疗方案还在不断创新和优化,本共识在循证医学的指导下,强调需根据个体化原则选择治疗方案,进一步规范了诊断及治疗,进而保障患者疗效及生活质量㊂[参考文献][1]S c h a f f L R,G r o mm e s C.P r i m a r y c e n t r a l n e r v o u s s y s t e ml y m p h o m a[J].B l o o d,2022,140(9):971-979.[2] C h e n T,L i u Y,W a n g Y,e t a l.E v i d e n c e-b a s e d e x p e r tc o n s e n s u so nt h e m a n a g e m e n to f p r i m a r y c e n t r a ln e r v o u ss y s t e ml y m p h o m a i n C h i n a[J].J H e m a t o lO n c o l,2022,15(1):136.[3]中国临床肿瘤学会(C S C O).中国临床肿瘤学会(C S C O)淋巴瘤诊疗指南2022[M].北京:人民卫生出版社,2022:87-104.[4] K a w a iN,O k u b o S,M i y a k e K,e ta l.U s eo fP E T i nt h ed i a g n o s i s o f p r i m a r y C N S l y m p h o m a i n p a t ie n t sw i t h a t y p i c a lM Rf i n d i n g s[J].A n nN u c lM e d,2010,24(5):335-343.[5]靳飞,房娜,刘震,等.18F-F D G P E T/C T在胶质瘤分级及其与原发性中枢神经系统淋巴瘤鉴别诊断中的价值[J].临床放射学杂志,2021,40(4):669-673.[6] D u f o u r J,C h o q u e t S,H o a n g-X u a nK,e t a l.S y s t e m i c r e l a p s e so f p r i m a r y C N S l y m p h o m a s(P C N S L):aL O Cn e t w o r ks t u d y[J].A n nH e m a t o l,2023,102(5):1159-1169.[7] R a eA I,M e h t aA,C l o n e y M,e ta l.C r a n i o t o m y a n ds u r v i v a lf o r p r i m a r y c e n t r a l n e r v o u s s y s t e m l y m p h o m a[J].N e u r o s u r g e r y,2019,84(4):935-944.[8]S c h e i c h e lF,M a r h o l d F,P i n g g e r a D,e t a l.I n f l u e n c e o fp r e o p e r a t i v ec o r t i c o s t e r o i dt r e a t m e n to n r a t e o fd i a g n o s t i cs u r g e r i e si n p r i m a r y c e n t r a ln e r v o u ss y s t e m l y m p h o m a:am u l t i c e n t e r r e t r o s p e c t i v es t u d y[J].B M C C a n c e r,2021,21(1):754.[9] C h e n g L,Z h u H,W a n g J,e ta l.C l i n i c a l f e a t u r e s,d i a g n o s i s,a n d t r e a t m e n t o f p r i m a r y i n t r a v e n t r i c u l a r l y m p h o m a:i n s i g h t sf r o mam o n o c e n t r i cc a s es e r i e s[J].F r o n tN e u r o l,2022,13:920505.[10]v a nd e r M e u l e n M,D i r v e n L,H a b e t s E J J,e ta l.C o g n i t i v ef u n c t i o n i ng a n dh e a l t h-r e l a t e d q u a li t y o f l i f e i n p a t i e n t sw i t hn e w l y d i a g n o s e d p r i m a r y C N S l y m p h o m a:a s y s t e m a t i c r e v i e w[J].L a n c e tO n c o l,2018,19(8):e407-e418. [11]J i aX,W a n g Z,H u a n g F,e ta l.A c o m p a r i s o no ft h e m i n i-m e n t a l s t a t e e x a m i n a t i o n(MM S E)w i t h t h e m o n t r e a lc o g n i t i v e a s s e s s m e n t(M o C A)f o rm i l dc o g n i t i v e i m p a i r m e n ts c r e e n i n g i n C h i n e s e m i d d l e-a g e d a n d o l d e r p o p u l a t i o n:ac r o s s-s e c t i o n a l s t ud y[J].B M CP s y c h i a t r y,2021,21(1):485.[12] C o c k sK,W e l l sJ R,J o h n s o nC,e ta l.C o n t e n tv a l i d i t y o f t h eE O R T C q u a l i t y o fl i f e q u e s t i o n n a i r e Q L Q-C30f o r u s ei nc a n c e r[J].E u r JC a n c e r,2023,178:128-138.[13] A r v a n i t i sC D,F e r r a r oG B,J a i n R K.T h eb l o o d-b r a i nb a r r i e ra n db l o o d-t u m o u rb a r r i e ri n b r a i nt u m o u r sa n d m e t a s t a s e s[J].N a tR e vC a n c e r,2020,20(1):26-41.[14] H i r a g aS,A r i t a N,O h n i s h iT,e ta l.R a p i di n f u s i o no fh i g h-d o se m e t h o t r e x a t e r e s u l t i n g i n e n h a n c e d p e n e t r a t i o n i n t oc e r e b r o s p i n a l f l u id a n d i n te n s if i e d t u m o r r e s p o n s e i n p r i m a r yc e n t r a l n e r v o u s s y s t e ml y m p h o m a s[J].JN e u r o s u r g,1999,91(2):221-230.[15] H o a n g-X u a n K,D e c k e r t M,F e r r e r i A J M,e ta l.E u r o p e a na s s o c i a t i o n o f n e u r o-o n c o l o g y(E A N O)g u i d e l i n e s f o rt r e a t m e n t o f p r i m a r y c e n t r a l n e r v o u s s y s t e m l y m p h o m a(P C N S L)[J].N e u r oO n c o l,2023,25(1):37-53.[16] R a m s e y L B,B a l i s F M,O'B r i e n MM,e t a l.C o n s e n s u sg u i d e l i n e f o ru s eo f g l u c a r p i d a s ei n p a t i e n t s w i t hh i g h-d o s em e t h o t r e x a t e i n d u c e d a c u t e k i d n e y i n j u r y a n d d e l a y e dm e t h o t r e x a t e c l e a r a n c e[J].O n c o l o g i s t,2018,23(1):52-61.[17] F o x C P,P h i l l i p s E H,S m i t h J,e t a l.G u i d e l i n e sf o rt h ed i a g n o s i s a n dm a n a ge m e n t of p r i m a r y c e n t r a l n e r v o u s s y s t e md i f f u se l a r g eB-c e l l l y m p h o m a[J].B rJ H a e m a t o l,2019,184(3):348-363.[18] Z h u J J,G e r s t n e r E R,E n g l e r D A,e t a l.H i g h-d o s em e t h o t r e x a t e f o r e l d e r l y p a t i e n t s w i t h p r i m a r y C N Sl y m p h o m a[J].N e u r oO n c o l,2009,11(2):211-215. [19] R u b e n s t e i nJ L,C o m b s D,R o s e n b e r g J,e t a l.R i t u x i m a bt h e r a p y f o r C N Sl y m p h o m a s:t a r g e t i n g t h el e p t o m e n i n g e a lc o m p a r t m e n t[J].B l o o d,2003,101(2):466-468.[20]I w a m o t oF M,S c h w a r t zJ,P a n d i t-T a s k a r N,e ta l.S t u d y o fr a d i o l a b e l e d i n d i u m-111a n d y t t r i u m-90i b r i t u m o m a b t i u x e t a ni n p r i m a r y c e n t r a ln e r v o u ss y s t e m l y m p h o m a[J].C a n c e r,2007,110(11):2528-2534.[21] F e r r e r iA J,C w y n a r s k i K,P u l c z y n s k iE,e ta l.I n t e r n a t i o n a lE x t r a n o d a l L y m p h o m a S t u d y G r o u p(I E L S G).C h e m o i mm u n o t h e r a p y w i t h m e t h o t r e x a t e,c y t a r a b i n e,t h i o t e p a,a n dr i t u x i m a b(MA T R i xr e g i m e n)i n p a t i e n t sw i t hp r i m a r y C N S l y m p h o m a:r e s u l t s o f t h e f i r s t r a n d o m i s a t i o no ft h e I n t e r n a t i o n a l E x t r a n o d a l L y m p h o m a S t u d y G r o u p-32㊃8631㊃河北医科大学学报第44卷第12期(I E L S G32)p h a s e2t r i a l[J].L a n c e tH a e m a t o l,2016,3(5):e217-227.[22] Y uJ,D u H,Y e X,e ta l.H i g h-d o s e m e t h o t r e x a t e-b a s e dr e g i m e n sa n d p o s t-r e m i s s i o nc o n s o l i d a t i o nf o rt r e a t m e n to fn e w l y d i a g n o s e d p r i m a r y C N Sl y m p h o m a:m e t a-a n a l y s i so fc l i n i c a l t r i a l s[J].S c i R e p,2021,11(1):2125.[23] H o u i l l i e rC,D u r e a uS,T a i l l a n d i e rL,e t a l.L O Cn e t w o r kf o rC N S l y m p h o m a.R a d i o t h e r a p y o r a u t o l o g o u s s t e m-c e l lt r a n s p l a n t a t i o n f o r p r i m a r y c n s l y m p h o m a i n p a t i e n t sa g e60y e a r s a n d y o u n g e r:l o n g-t e r mr e s u l t s o f t h e r a n d o m i z e d p h a s eⅡP R E C I SS t u d y[J].JC l i n O n c o l,2022,40(32):3692-3698.[24] B a t c h e l o rT,G i r i S,R u p p e r tAS,e t a l.M y e l o a b l a t i v ev e r s u sn o n-m y e l o a b l a t i v e c o n s o l i d a t i v e c h e m o t h e r a p y f o r n e w l yd i a g n o se d p r i m a r y c e n t r a l n e r v o u s s y s t e ml y m p h o m a:R e s u l t so f i n d u c t i o n t h e r a p y i nA l l i a n c e51101[J].J C l i nO n c o l,2020,38(15_s u p p l):8042-8042.[25] P e n t s o v a E,D e a n g e l i s L M,O m u r o A.M e t h o t r e x a t e r e-c h a l l e n g e f o r r e c u r r e n t p r i m a r y c e n t r a l n e r v o u s s y s t e ml y m p h o m a[J].JN e u r o o n c o l,2014,117(1):161-165.[26] C a oT,W a n g Z,Z h uX.T h e i mm u n o m o d u l a t o r y f u n c t i o n s o fB T Ki n h i b i t i o n i nt h e c e n t r a l n e r v o u s s y s t e m[J].J I n f l a mmR e s,2022,15:6427-6438.[27]S o u s s a i n C,C h o q u e t S,B l o n s k i M,e t a l.I b r u t i n i bm o n o t h e r a p y f o r r e l a p s e o r r e f r a c t o r y p r i m a r y C N Sl y m p h o m a a n d p r i m a r y v i t r e o r e t i n a l l y m p h o m a:F i n a l a n a l y s i so ft h e p h a s eⅡ'p r o o f-o f-c o n c e p t'i L O C s t u d y b y t h eL y m p h o m a s t u d y a s s o c i a t i o n(L Y S A)a n dt h eF r e n c ho c u l o-c e r e b r a l l y m p h o m a(L O C)n e t w o r k[J].E u r JC a n c e r,2019,117:121-130.(本文编辑:杜媛鲲)㊃9631㊃赵煜微等‘2022年原发性中枢神经系统淋巴瘤治疗中国专家循证共识“解读。

相关主题
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Clinical investigation of the interface pressure in the trans-tibial socket with Dermo and Seal-In X5liner during walking and their effect on patient satisfactionSadeeq Ali ⁎,Noor Azuan Abu Osman,Niyousha Mortaza,Arezoo Eshraghi,Hossein Gholizadeh,Wan Abu Bakar Bin Wan AbasDepartment of Biomedical Engineering,Faculty of Engineering,University of Malaya,Malaysiaa b s t r a c ta r t i c l e i n f o Article history:Received 10April 2012Accepted 6June 2012Keywords:PressureTranstibial prostheses Amputee Satisfaction Prosthetic linerBackground:The interface pressure between the residual limb and prosthetic socket has a signi ficant effect on an amputee's satisfaction and comfort.Liners provide a comfortable interface by adding a soft cushion be-tween the residual limb and the socket.The Dermo and the Seal-In X5liner are two new interface systems and,due to their relative infancy,very little are known about their effect on patient satisfaction.The aim of this study was to compare the interface pressure with these two liners and their effect on patient satisfaction.Methods:Nine unilateral transtibial amputees participated in the study.Two prostheses were fabricated for each amputee,one with the Seal-In liner and one with the Dermo liner.Interface pressure was measured at the anterior,posterior,medial and lateral regions during walking on the level ground.Each subject filled in a Prosthetic Evaluation Questionnaire (PEQ)regarding the satisfaction with the two liners.Findings :The mean peak pressures with the Seal-In liner was 34.0%higher at the anterior,24.0%higher at the posterior and 7.0%higher at the medial regions of the socket (P =0.008,P =0.046,P =0.025)than it was with the Dermo Liner.There were no signi ficant differences in the mean peak pressures between the two liners at the lateral regions.In addition,signi ficant difference was found between the two liners both for sat-isfaction and problems (P b 0.05).Interpretation :There was less interface pressure between the socket and the residual limb with the Dermo liner.The results indicated that the Dermo liner provides more comfort in the socket than the Seal-In liner.©2012Elsevier Ltd.All rights reserved.1.IntroductionTranstibial amputation patients need prosthetic devices after ampu-tation surgery in order to regain their functional mobility and appear-ance (Wolf et al.,2009).The socket design plays a signi ficant role in determining the quality of the fit and provides an interface between the prosthesis and the residual limb (Jia et al.,2004).Appropriate socket fitting in prosthetic devices can have a signi ficant effect on the patient's comfort,mobility and level of satisfaction with their prosthesis (Kristinsson,1993;McCurdie et al.,1997).Skin problems are common in prosthetic users and these can appear in the form of rashes,ulcers,irritation and allergies.Their presence is com-monly attributed to one of several reasons:the inadaptability of the skin,due to the intolerance of pressure by the prosthetic socket on the residual limb;bacterial proliferation as a result of a snugly-fitted socket that causes entrapment of perspiration in a closed environment;skin irritation or al-lergic reaction due to the materials used in the prosthetic socket and liners (Dudek et al.,2005;Dudek et al.,2006).Lower limb amputeescommonly experienced residual limb skin problems with the use of the prostheses (Laing et al.,2011).Amputees often need to stop using the prosthesis entirely for a period of time as a result of the pain and dis-comfort caused by such skin problems.This condition can badly effect the mental wellbeing of a patient and will ultimately impact their satis-faction with a device (Meulenbelt et al.,2006).It is crucial that the risk of these skin complications is taken into con-sideration during the design of the prosthetic socket and that the design of the device is based on a good understanding of the pressure that can occur between the amputee's residual limb and the prosthetic socket (Jia et al.,2008).In order to reduce the possibility of these skin issues oc-curring,liners are fit inside the socket to provide the residual limb with a soft cushion.Liners have a direct contact with the residual limb inside the socket and play a signi ficant role in transferring the load and distrib-uting the interface pressure over the residual limb (Coleman et al.,2004;Lin et al.,2004).Polyethylene foam liners with patellar tendon bearing (PTB)prosthet-ic socket have been in use since 1950;however,modern liners,which are generally made from silicone and other elastomers,offer better suspen-sion and cushion (Dietzen et al.,1991;Haberman et al.,1992;Madigan and Fillauer,1991).Silicon and gel liners were introduced worldwide in the mid 1990s and were designed to reduce shear forces and produce bet-ter interface bonds between the residual limb and the socket (Van de WegClinical Biomechanics 27(2012)943–948⁎Corresponding author.E-mail addresses:sadeeqcpo@.my (S.Ali),azuan@.my (N.A.A.Osman),n.mortaza@.my (N.Mortaza),arezoo@.my (A.Eshraghi),gholizadeh@.my (H.Gholizadeh),drirwan1@.my (W.A.B.B.WanAbas).0268-0033/$–see front matter ©2012Elsevier Ltd.All rights reserved.doi:10.1016/j.clinbiomech.2012.06.004Contents lists available at SciVerse ScienceDirectClinical Biomechanicsj o ur n a l h o m e p a g e :w w w.e l s e v i e r.c o m /l o c a t e /c l i n b i o m e c hand Van Der Windt,2005).One of these silicone liners is known as the Seal-In X5liner(Fig.1).It was introduced by Ossur(Reykjavik,Iceland) and is composed offive seals that conform to the shape of the internal socket wall and the residual limb(Gholizadeh et al.,in press).Through this,the Seal-In X5liner provides suspension without the need for an ex-ternal sleeve or lock and claim to be a good choice for high impact activ-ities.The Dermo liner(Reykjavik,Iceland)is also made of silicone; however,unlike the Seal-In X5liner,it cushions the limb and pro-vides suspension through a shuttle lock system(Fig.1).Many studies have been carried out to investigate the interface pres-sure and stresses(Jia et al.,2005;Sanders et al.,1998;Wolf et al.,2009). Some of them compared the socket pressure of polyethylene foam liners with silicone liners(Dumbleton et al.,2009).Some studies have investi-gated the effect of various casting techniques or socket design on the socket-residual limb interface pressure(Dumbleton et al.,2009;Jia et al.,2005;Lee and Zhang,2007),while other studies have focused on the effect of alignment on interface pressure(Jia et al.,2008).However, none of these studies compared the effect of a Dermo liner that used a shuttle lock with a sealing system such as the Seal-In X5liner.In the Seal-In X5liner,the seals have the potential to impose extra pressure over the residual limb.This can cause excessive pressure,that in it can be a source of problems for diabetic patients or amputees with sensitive residual limbs.The aim of this clinical study was to measure and evaluate the interface pressure in the Dermo liner during normal walking and compare it with the Seal-In X5liner.The study also aimed to assess the effect that the two liners had on patients'satisfaction.2.Methodology2.1.SubjectsA total of nine unilateral transtibial amputees(7males,2females) participated in this study.All the subjects were selected from the Depart-ment of Rehabilitation of the University Malaya Medical Centre(UMMC), Kuala Lumpur,Malaysia.The ethics committee of UMMC approved this study,and informed written approval was attained from all the subjects. The inclusion criteria consisted of a minimum15cm residual limb length (from the mid patella to the distal end of residual limb),no wound and ulcers in the residual limb,no volume changes,and the ability to walk without the use of assistive devices.It was a requirement that the partic-ipants are experienced prosthetic users(more than6months).A sample of convenience is used for this study.2.2.Prosthetic interventionsTwo transtibial prostheses were made for each subject,one with the Dermo liner with shuttle lock(Icelock-200series)and another with the Seal-In X5liner with valve(Icelock Expulsion,Valve551).All the prosthe-ses were fabricated with Flex-Foot Talux(Ossur,Reykjavik,Iceland).One registered prosthetist fabricated all the prostheses to avoid alterations due to manufacturing,alignment andfitting.A total surface bearing (TSB)socket was fabricated for all the subjects(Staats and Lundt,1987). In order to become familiar with their new prosthetic devices,the sub-jects practiced walking in the motion analysis laboratory(Biomedical Engineering Department,University of Malaya,Malaysia)and the pros-thetist adjusted thefitting of the socket and alignment according to their needs.Subjects were required to use their prostheses for a minimum of four weeks.The subjects were asked to visit the brace and limb labora-tory for follow up on a weekly basis to ensure that thefit of the prosthesis remained suitable.2.3.Experimental setting and proceduresAfter four weeks of acclimation,the subjects attended the motion lab-oratory for pressure measurements.Four F-Socket sensors arrays9811 (Tekscan Inc.,South Boston,USA)were attached to the residual limb.The sensor arrays were positioned on the anterior,posterior,medial and lateral aspects of the residual limb(Fig.1).The mid patella was taken as the reference line for the placement of medial,lateral and anterior sen-sors.The posterior sensor was positioned approximately1cm above the posterior trim line of the socket.Each sensor was trimmed tofit to the re-sidual limb contours.To prevent sensor arrays displacement,the residual limb was covered with a cellophane cover.Following this,each sensor was attached to the cellophane covers by an adhesive spray(3M Spray Mount Adhesive,3M corporate,St.Paul,USA).This sensor arrangement provided a pressure map that covered90%of the residual limb during the gait.Tekscan software version6.51was used to record the interface pressure.A Tekscan pressure bladder(PB100T,South Boston,USA)was used to equilibrate and calibrate the sensor arrays.Sensor arrays were placed in-side the bladder and,according to the manufacturer's instructions,were subjected to a pressure of100kPa.Calibration was carried out based on each subject's body weight.That is,the applied pressure for calibration was the ratio of the subject's body weight to the respective sensor area (Buis,1997).2.4.Walkway and collection of the dataSubjects were asked to walk at a self-selected speed on a walkway that was9-meter long and5-meter wide.Prior to the data collection ac-tivity,the subjects were requested to walk on the walkway to familiar-ize with the procedure.Data acquisition was performed for12seconds with a sample rate of50Hz.The subjects completed four consecutive trials on the walkway and in each trial approximately eight to nine steps were taken.The middle step of each trial was chosen.The mean peak pressures(MPP)of four trials were employed for the purposes of statistical analyses.2.5.QuestionnaireAfter the experiments were completed,each subject completed a questionnaire that asked for further information about their satisfaction with the two liners.Various parts of the Prosthetics Evaluation Ques-tionnaire(PEQ)were adopted for this questionnaire.The questionnaire was composed of the following three sections:1-Demographic variables(sex,age,weight,height,amputation side, cause of amputation,activity level and time sincefirst prosthesis). 2-Satisfaction(fitting,donning and doffing,suspension,sitting,walk-ing on level surfaces,ascending and descending stairs,walking on uneven ground,cosmesis and overall satisfaction).3-Problems(Wound,skin irritation,sweating,pistoning,rotation,re-sidual limb swelling,smell,sounds and residual limbpain).Fig.1.(A)Seal-In Liner(B)Dermo Liner(C)Sensors attachments on residual limb.944S.Ali et al./Clinical Biomechanics27(2012)943–948A scale of0–100was used to score all the questions,where100indi-cated“complete satisfaction or no problems”and0indicated“unsatisfied or extremely bothered.”2.6.Analysis of dataSince the sample size of this study was small(N=9),non-parametric test were used to analyze the data.Therefore we used Wilcoxon signed ranks test to compare within-subject pressure measurements with the Dermo liner and Seal-In X5liner for different regions in the socket.We also used Wilcoxon signed rank test to compare the satisfaction with the two liners.For the overall scores,which were distributed normally, paired-samples t-test was applied.Statistical analyses were carried out using Version20of SPSS,statistical software(SPSS,Chicago,IL).3.Results3.1.Subject's ProfileThe mean age of the subjects was(mean=49.3,SD=15.0)and their activity level,based on the Medicare Functional Classification Level(MFCL)(Dudek et al.,2008),was K2–K3and K3–K4.All the subjects had undergone amputation surgery at least three and half years prior to the study.The participants'demographic information is shown in Table1.3.2.Interface pressurePressure measurements were extracted in twelve regions of the re-sidual limb.The mean of peak pressures are presented separately in Table2.The pressures of the four major regions of the residual limb are presented in Fig.2.In both the anterior and posterior regions,the mean pressures for the proximal,middle subregion areas were signifi-cantly higher(P b0.05)with the Seal-In X5liner than they were with the Dermo liner.In both the lateral and medial regions,the pressure in the middle and distal subregion area was significantly higher(P b0.05).The MPP for the four major regions of the residual limb was also obtained.The MPP values for the whole anterior region of the residual limb was significantly higher for the Seal-In X5liner compared to the Dermo liner(P=0.008,Z=−2.66;mean=84.90kPa,SD=30.46; mean=60.2kPa,SD=13.00,respectively).Moreover,at the posteri-or region,MPP was significantly higher with the Seal-In X5liner com-pared to the Dermo liner(P=0.046,Z=−1.99;mean=74.51kPa, SD=12.04;mean=54.10kPa,SD=11.21,respectively).There was a statistically significant difference between the pressure values for the two liners in the medial region of the residual limb,(P=0.025,Z=−2.24;Dermo:mean=50.00kPa,SD=12.34;Seal-In X5:mean= 53.80kPa,SD=9.45).There was no statistically significant difference between the pressure values for the two liners in the lateral regions of the residual limb(P=0.601,Z=−0.42;Dermo:mean=50.00kPa, SD=11.21;Seal-In X5:mean=51.50kPa,SD=7.70)(Fig.3).3.3.QuestionnaireInfive out of the nine questions on the satisfaction scale of the ques-tionnaire,the Wilcoxon Signed Rank Test revealed statistically significant higher scores for the Dermo liner than those for the Seal-In X5liner. However,the Seal-In X5liner scored better on the question about the suspension of the prosthesis(Table3).In the element of the questionnaire that was aimed at assessing problems with a device,the Wilcoxon Signed Rank test showed signifi-cantly higher scores acrossfive items for the Dermo liner and two items (including pistoning within the socket and unwanted sounds)for the Seal-In X5liner(Table3).The overall scores(average)of the two scales of the questionnaire were also calculated and compared for the two liners.A paired-samples t-test was performed to compare the scores of satisfaction and problems scales for the Dermo and Seal-In liners.In both scales,the subjects assigned significantly higher scores to the Dermo liner(P b0.05)than they did to the Seal-In liner.4.DiscussionBiomechanical understanding of the interface pressure between the socket and residual limb is one of the primary objectives in prostheticTable1Demographic variables of the subjects.Weight(SD)72.44(16.30)Kg Height(SD)169.11(7.78)CmFemale3(33.30%) Gender(%)Male6(66.70%)Body mass index(SD)25.22(4.83)Age of the patient(SD)49.33(15.05)K2-K38(88.90%) Activity level(%)K3-K41(11.10%)Right4(44.44%) Amputation side(%)Left5(55.55%)Trauma3(33.30%)Cause of amputation(%)Peripheral Vascular Disease(PVD)Diabetic 2(22.20%)4(44.50%)Table2Mean peak pressure(kPa)at the anterior,posterior,medial and lateral subregions.Liner type Anterior PosteriorProximal Middle Distal Proximal Middle DistalDermoLiner60.9(19.1)62.7(11.5)57.0(14.4)56.6(12.7)62.8(23.2)59.7(25.6)Seal-In X5Liner85.3(31.3)86.5(29.6)82.8(35.4)67.4(11.9)82.7(22.7)78.8(26.2)P-value0.038⁎0.021⁎0.011⁎0.046⁎0.028⁎0.260Z−2.07−2.31−2.54−1.99−2.19−1.125Liner type Medial LateralProximal Middle Distal Proximal Middle DistalDermoLiner47.6(13.9)49.9(12.8)49.5(19.0)53.0(26.3)56.1(14.5)48.2(9.4)Seal-In X5Liner47.7(10.2)63.0(17.3)57.6(17.5)51.0(28.7)56.1(5.8)60.8(17.2)P-value0.6740.008⁎0.028⁎0.7670.8890.093Z−0.42−2.66−2.19−0.29−0.14−1.68*Significant differences between the Dermo and Seal-InX5liner.Fig.2.Mean peak pressure for the four major regions of the stump.The asterisks(*)indicate significant differences between the Dermo and Seal-In X5liner.945S.Ali et al./Clinical Biomechanics27(2012)943–948rehabilitation (Mak et al.,2001).The level of patient satisfaction with a prosthesis is said to be greatly dependent on the proper allocation of in-terface pressures at pressure-relief and pressure-tolerant areas of the residual limb (Haberman et al.,1992).Residual limb and socket inter-face pressure is considered to be of high signi ficance when assessing the biomechanics of the dissimilar socket designs.Measuring the de-gree of these pressures is a direct technique that can be used to evaluate the comfort and fit of the socket (Laing et al.,2011).Two different inter-face liners for transtibial prosthesis were examined in this study:the Seal-In X5liner and the Dermo liner with shuttle lock system.The results of the study revealed that the MPP value in the Seal-In X5liner was signi ficantly higher for the whole anterior and posterior re-gion of the residual limb than it was with the Dermo liner with shuttle lock.The average MPP difference was 34.04%at the anterior and 24.04%at the posterior region.In the study,the anterior proximal subregion pressure was lower than the anterior middle subregion for both liners.This finding is similar to the results of a study conducted by Dumbleton et al.,which found that the interface pressure was the lowest at the proximal region of the residual limb (Dumbleton et al.,2009).This pre-sent study showed that the interface pressure in the Seal-In X5was higher at the middle sub-region of the residual limb than it was withthe distal and proximal subregions,both in the anterior/posterior and the medial/lateral aspects.This higher pressure might be associated with the five seals around the liner,which provide an airtight fit inside the socket.In the current study,the MPP at posterior-proximal region were recorded as 56.6kPa,and 67.4kPa for the Dermo liner and Seal-In X5liner respectively.Beil and Street compared the interface pressure be-tween the urethane liners using suction socket and pin and lock socket.Their study revealed average pressures of 68.6kPa and 66.4kPa at the posterior proximal region for the suction and TSB socket respectively (Beil and Street,2004).This is consistent with the current study 's findings with regard to the Dermo liner.Overall,in the current study,the pressure was higher at all the subregions of anterior and posterior regions with the Seal-In X5liner.In the present study,there was a statistically signi ficant difference between the two liners on the whole medial region and no statistically signi ficant differences between the two liners on the whole lateral re-gion of the residual limb were recorded.MPP values were signi ficantly higher (P b 0.05)for the Seal-In X5liner at the middle and distal subre-gions.This is also consistent with a study by Dumbleton et al.,which identi fied higher pressure at the lateral distal end (Dumbleton et al.,2009).Three of the subjects in the current study refused to continueTable 3Satisfaction and problems with Dermo and the Seal-In liner.Dermo liner mean (SD)Seal-In liner mean (SD)P -value Z Effect size SatisfactionFit of prosthesis78.1(5.6)↑73.3(5.6)0.01a −2.460.58Ability to don and doff the prosthesis 86.7(7.9)↑50.0(7.1)0.01a −2.680.63Ability to sit with the prosthesis 77.2(7.1)75.6(5.3)0.47NS b -Ability to walk with the prosthesis 84.2(5.3)↑76.1(5.5)0.01a −2.720.64Ability to walk on uneven terrain75.8(6.4)↑72.8(5.7)0.03a −2.120.50Ability to walk up and down on stairs 75.0(9.4)77.8(6.2)0.25NS -Suspension82.2(3.6)85.6(5.8)↑0.03a −2.120.50Appearance of the prosthesis81.4(5.1)83.9(4.2)0.13NS -Overall satisfaction with the prosthesis 84.7(5.7)↑70.6(4.6)0.01a −2.090.49Overall score80.6(5.1)↑73.9(4.0)0.00at =9.020.91Problems/complaints Sweating76.7(6.6)73.9(9.6)0.49NS -Wounds/ingrown hairs/blisters 87.8(7.9)↑82.2(7.9)0.04a −2.060.49Skin irritations84.4(8.8)↑77.2(9.7)0.04a −2.030.48Pistoning within the socket 78.9(6.0)86.7(5.6)↑0.01a −2.140.50Rotation within the socket 84.6(8.1)82.8(9.1)0.46NS -Swelling of the stump87.8(6.2)↑78.6(8.4)0.01a −2.540.60Unpleasant smell of prosthesis or stump 82.8(7.5)↑74.4(4.6)0.02a −2.390.56Unwanted sounds 77.8(3.6)83.9(4.9)↑0.01a −2.420.57Pain in stump 86.7(4.3)↑73.0(8.0)0.01a −2.710.64Overall Score83.0(4.6)↑79.2(5.9)0.01a t=3.200.57a Signi ficant differences between the Dermo and Seal-In liner.bNon signi ficant.Fig.3.Mean peak pressure in all subsections of the stump.The asterisks (*)indicate signi ficant differences between the Dermo ®and Seal-In ®liner.946S.Ali et al./Clinical Biomechanics 27(2012)943–948using the prosthesis with the Seal-In X5liner on a long-term basis as they felt tightness and excessive pressure on the residual limb,particu-larly in the areas where the seals were located.Significant differences were found between the two liners with re-spect to the levels of patient satisfaction and the problems they expe-rienced.Subjects were more satisfied with the Dermo liner(P b0.05) than they were with the Seal-In X5liner.The overall score was (mean=80.59,SD=5.14)for the Dermo liner with shuttle lock compared to(mean=73.95,SD=4.03)for the Seal-In X5liner.The av-erage difference across the9questions on the satisfaction scale of the questionnaire was8.67%higher for the Dermo liner and the mean dif-ference for the problem and complaints scale of the questionnaire was 4.69%higher for the Dermo liner than the Seal-In X5liner.These differ-ences were both statistically significant.The results of this study revealed that the subjects preferred the Dermo liner with shuttle lock and,as such,it supports thefindings of McCurdie et al.,which clearly reported the preference to locking liners. Moreover,it is consistent with a recent study by Gohlezadeh et al., which revealed higher patient satisfaction with the Dermo liner and shuttle lock when compared with the Seal-In X5liner.However,Linde et al.stated that experts in thefield of rehabilitation were more satisfied with the locking liners(Linde et al.,2004).A study by Astrom and Stenstrom revealed that locking liners pro-vided more comfort and a betterfit within the socket(Åström and Stenström,2004)and theirfindings are consistent with those of the current study,where the subjects were more satisfied with thefit of the Dermo liner with shuttle lock.Another study by Klute et al. established that the participants were more satisfied with the locking system(Klute et al.,2011).The results of the present study revealed that a subject's ability to walk with the prosthesis was higher and they walked more comfortably with the Dermo liner than they did the Seal-In X5liner.Similarfindings were established in a study by Hatfield and Morrison(Hatfield and Morrison,2001).The socketfit and suspension in prostheses have significant impact on the user's mobility,comfort and satisfaction(Baars and Geertzen, 2005).Within the questionnaire,the subjects rated the Seal-In X5liner higher than the Dermo liner.Gholizadeh et al.also mentioned improved suspension with the Seal-In X5liner(Gholizadeh et al.,2011).However, thefindings of the current study contradict the study of Cluitmans et al.,where enhanced suspension was measured with the locking liners(Cluitmans et al.,1994).The ease with which a subject can don and doff a prosthetic device plays a significant role in prosthetic use and their satisfaction with that device(Baars et al.,2008;Gauthier-Gagnon et al.,1999).This study re-vealed that the subjects found doffing and donning the Seal-In X5liner much more difficult than they did the Dermo liner with shuttle lock.Sim-ilarfindings were revealed by Gholizadeh et al.The subjects involved in this study,all of whom were over50years old,were not ready to accept the Seal-In X5liner because of difficulties in donning and doffing the de-vice and the excessive tightness of the socket.Furthermore,the satisfac-tion score was higher for the Dermo liner with shuttle lock than it was for the Seal-In X5liner,with the exception of suspension.Moreover,statis-tical analysis showed significantly fewer problems with the Dermo liner with the shuttle lock.It is acknowledged that thefindings of the current study are limited to only nine subjects and to normal walking on level ground.Further clinical studies are required to evaluate the interface between the liner and socket and satisfaction during walking on uneven ground,stairs and slopes.5.ConclusionThe selection of good prosthetic components is considered to present a challenging task in amputee rehabilitation.The result of the interface pressure analyses showed less pressure within the socket wearing the Dermo liner.Moreover,the subjects had less problems and complaints with the Dermo liner.Hence,it can be concluded that the Dermo liner provides more comfortable socket-residual limb interface than the Seal-In X5liner.However,despite this,the Seal-In X5liner offers better sus-pension.All these issues should be taken into account when choosing prosthetic components for amputees.AcknowledgmentsThis research was funded by the Malaysia UM/MOHE HIR grant.The support of Ossur(Reykjavik,Iceland)by donation of prosthetic compo-nents is gratefully acknowledged.ReferencesÅström,I.,Stenström,A.,2004.Effect on gait and socket comfort in unilateral trans-tibial amputees after exchange to a polyurethane concept.Prosthet.Orthot.Int.28,28–36. Baars,E.,Geertzen,J.,2005.Literature review of the possible advantages of silicon liner socket use in trans-tibial prostheses.Prosthet.Orthot.Int.29,27–37.Baars,E.C.T.,Dijkstra,Pieter Ubele,Geertzen,Jan H B,2008.Skin problems of the stump and hand function in lower limb amputees:a historic cohort study.Prosthet.Orthot.Int.32,179–185.Beil,T.L.,Street,G.M.,parison of interface pressures with pin and suction suspension systems.J.Rehabil.Res.Dev.41,821–828.Buis,A.C.,1997.Calibration problems encountered while monitoring stump/socket in-terface pressures with force sensing resistors:techniques adopted to minimise in-accuracies.Prosthet.Orthot.Int.21,179–182.Cluitmans,J.,Geboers,M.,Deckers,J.,Rings,F.,1994.Experiences with respect to the ICEROSS system for trans-tibial prostheses.Prosthet.Orthot.Int.18,78–83. Coleman,K.L.,Boone,D.A.,Laing,L.S.,Mathews,D.E.,Smith,D.G.,2004.Quantification of prosthetic outcomes:elastomeric gel liner with locking pin suspension versus polyeth-ylene foam liner with neoprene sleeve suspension.J.Rehabil.Res.Dev.41,591–602. Dietzen,C.J.,Harshberger,J.,Pidikiti,R.D.,1991.Suction sock suspension for above-knee prostheses.JPO3,90–93.Dudek,N.L.,Marks,M.B.,Marshall,S.C.,Chardon,J.P.,2005.Dermatologic conditions as-sociated with use of a lower-extremity prosthesis.Arch.Phys.Med.Rehabil.86, 659–663.Dudek,N.L.,Marks,M.B.,Marshall,S.C.,2006.Skin problems in an amputee clinic.Am.J.Phys.Med.Rehabil.85,424–429.Dudek,N.L.,Khan,O.D.,Lemaire,E.D.,Marks,M.B.,Saville,L.,Maffiulletti,N.,2008.Am-bulation monitoring of transtibial amputation subjects with patient activity moni-tor versus pedometer.J.Rehabil.Res.45,577–585.Dumbleton,T.,Buis,A.W.P.,Mcfadyen,A.,Mchugh,B.F.,Mckay,G.,Murray,K.D.,Sexton, S.,2009.Dynamic interface pressure distributions of two transtibial prosthetic socket concepts.J.Rehabil.Res.Dev.46,405–416.Gauthier-Gagnon,C.,Grisé,M.C.,Potvin,D.,1999.Enabling factors related to prosthetic use by people with transtibial and transfemoral amputation.Arch.Phys.Med.Rehabil.80,706–713.Gholizadeh,H.,Osman,N.,Kamyab,M.,Eshraghi,A.,Abas,W.,Azam,M.,2011.Trans-tibial prosthetic socket pistoning:static evaluation of Seal-In®X5and Dermo®Liner using motion analysis system.Clin.Biomech.27,34–39.Gholizadeh,H.,Abu Osman,N.A.,Kamyab,M.,Eshraghi,A.,Lúvíksdóttir,Á.G.,Wan Abas,W.A.B.,in press.Clinical evaluation of two prosthetic suspension systems in a bilateral transtibial amputee.Am.J.Phys.Med.Rehabil.Haberman,L.J.,Bedotto,R.A.,Colodney,E.J.,1992.Silicone-only suspension(SOS)for the above-knee amputee.JPO4,76–85.Hatfield,A.,Morrison,J.,2001.Polyurethane gel liner usage in the Oxford Prosthetic Service.Prosthet.Orthot.Int.25,41–46.Jia,X.,Zhang,M.,Lee,W.C.C.,2004.Load transfer mechanics between trans-tibial pros-thetic socket and residual limb–dynamic effects.J.Biomech.37,1371–1377. Jia,X.,Zhang,M.,Li,X.,Lee,W.C.C.,2005.A quasi-dynamic nonlinearfinite element model to investigate prosthetic interface stresses during walking for trans-tibial amputees.Clin.Biomech.20,630–635.Jia,X.,Suo,S.,Meng,F.,Wang,R.,2008.Effects of alignment on interface pressure for transtibial amputee during walking.Disabil.Rehabil.Assist.Technol.3,339–343. Klute,G.K.,Berge,J.S.,Biggs,W.,Pongnumkul,S.,Popovic,Z.,Curless,B.,2011.Vacuum-assisted socket suspension compared with pin suspension for lower extremity amputees:effect onfit,activity,and limb volume.Arch.Phys.Med.Rehabil.92,1570–1575.Kristinsson,Ö.,1993.The ICEROSS concept:a discussion of a philosophy.Prosthet.Orthot.Int.17,49–55.Laing,S.,Lee,P.V.S.,Goh,J.C.H.,2011.Engineering a trans-tibial prosthetic socket for the lower limb amputee.Ann.Acad.Med.Singapore40,252–259.Lee,W.C.C.,Zhang,M.,ing computational simulation to aid in the prediction of socketfit:a preliminary study.Med.Eng.Phys.29,923–929.Lin,C.C.,Chang,C.H.,Wu,C.L.,Chung,K.C.,Liao,I.,2004.Effects of liner stiffness for trans-tibial prosthesis:afinite element contact model.Med.Eng.Phys.26,1–9. Linde,H.V.D.,Geertzen,J.,Hofstad,C.,Limbeek,J.V.,Postema,K.,2004.Prosthetic prescrip-tion in the Netherlands:an interview with clinical experts.Prosthet.Orthot.Int.28, 98–104.Madigan,R.R.,Fillauer,K.D.,1991.3-S prosthesis:a preliminary report.J.Pediatr.Orthop.11,112–117.947S.Ali et al./Clinical Biomechanics27(2012)943–948。

相关文档
最新文档